Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Definitions

• the standard of care therapies induce cell death by a cellular process called apoptosis.
• the apoptosis pathway is engaged by many common types of anti-cancer therapies and ionizing radiation, which contributes to the regression of tumors or the toxic side effects of treatment.
• the methods provided herein comprise administering agents that induce iron-dependent cell death in vivo and in some cases recruit immune cells, for instance leukocytes to tumors treated with iron-dependent cell death agents.
• the iron-dependent cell death agents include ferroptosis-inducing agents.
• the methods comprise: sustained administration of a therapeutic amount of a ferroptosis-inducing agent to a tissue, wherein the sustained administration of said therapeutic amount comprises providing to said tissue the ferroptosis-inducing agent in an amount sufficient to achieve a distribution of at least about 10 ng/mm 2 within said tissue for a period of at least 4 hours, thereby inducing ferroptosis in the tissue.
• the methods comprise: contacting a tissue in vivo with an effective amount of an iron-dependent cell death agent for a duration of time of at least 4 hours, wherein the tissue comprises one or more of: (a) a plurality of cells comprising a concentration of selenium greater than a selenium concentration in a corresponding normal tissue; (b) a plurality of cells comprising a concentration of iron greater than an iron concentration in a corresponding normal tissue; (c) a plurality of cells comprising a PUFA concentration greater than a PUFA concentration in a corresponding normal tissue; (d) a plurality of cells expressing one or more markers indicative of a mesenchymal state; and/or (e) a plurality of cells comprising a peroxidizability index (PI) greater than a PI in a corresponding normal tissue, wherein the effective amount of the iron-dependent cell death agent has a concentration of:
• the methods comprise: (a) contacting a mammalian tissue with a priming agent; (b) contacting the mammalian tissue in vivo with an effective amount of a ferroptosis- inducing agent for a duration of time of at least 4 hours, when a plurality of cells within the mammalian tissue are responsive to the priming agent as determined by detecting in the mammalian tissue: (i) a plurality of cells comprising a concentration of selenium greater than a selenium concentration in the mammalian tissue prior to contacting with the priming agent; (ii) a plurality of cells comprising a concentration of iron greater than an iron concentration in the mammalian tissue prior to contacting with the priming agent; (iii) a plurality of cells comprising a PUFA concentration greater than a PUFA concentration in the mammalian tissue prior to contacting with the prim
• the methods comprise: (a) contacting a mammalian tissue in vivo with an effective amount of a ferroptosis-inducing agent for a duration of time of at least 4 hours, wherein the ferroptosis- inducing agent induces targeted cell death in the mammalian tissue in vivo, and (b) contacting the mammalian tissue in vivo with an effective amount of a ferroptosis-inducing agent and a ferroptosis inhibitor, thereby modulation ferroptosis in vivo.
• an implantable microdevice configured for localized administration to a tissue comprising: (a) a cylindrical support structure having at least one microwell on a surface of or formed within the support structure; (b) a microdose of a ferroptosis-inducing agent in the at least one microwell; and (c) a compound release mechanism for sustained administration for controlling a release of the ferroptosis-inducing agent from the microwell, wherein the microdose of the ferroptosis-inducing agent forms a gradient of a sub-therapeutic dose or amount of the ferroptosis-inducing agent to an administration site within the tissue for a duration of time of at least 4 hours, wherein the microdevice is configured to permit implantation into the tissue using a catheter, cannula or biopsy needle, and wherein the microdevice is further configured to release the ferroptosis- inducing agent from the at least one microwell to the administration site within the apoptosisresistant
• systems for identifying ferroptosis induction in an animal model comprising: (a) an animal model comprising a target tissue of interest; (b) a microdevice configured to permit implantation into a tissue in the animal model using a catheter, cannula or biopsy needle comprising: (i) at least one microwell containing one or more active agents; (ii) a micro-dose of the one or more active agents in the at least one microwell; and (iii) a compound release mechanism comprising a polymeric matrix for controlling the release of the one or more active agents from the microwell into the tissue; wherein the system measures an outcome of ferroptosis induction in the animal model after administration of the one or more active agents into the tissue relative to a baseline tissue without administration of the one or more active agents, and identifying one or more active agents induces ferroptosis in the tissue.
• systems for screening for ferroptosis-induced cell death in vivo comprising: (a) an animal model comprising a target tissue of interest; (b) a microdevice configured to permit implantation into a tissue in the animal model using a catheter, cannula or biopsy needle comprising: (i) at least one microwell containing one or more active agents; (ii) at least one microwell containing one or more ferroptosis inhibitors; (ii) a micro-dose of the one or more active agents; and/or one or more ferroptosis inhibitors in the at least one microwell; and (iii) a compound release mechanism comprising a polymeric matrix for controlling the release of the one or more active agents from the microwell into the tissue; wherein the system measures an outcome of ferroptosis induction in the animal model after administration of the one or more active agents into the tissue relative to a baseline tissue without administration of the one or more active agents, wherein the system measures an outcome of ferroptosis
• compositions for the treatment of a disease or disorder wherein the compositions comprise any one of the agents in Table 1 or a combination of agents; and a system provided herein.
• compositions for the treatment of a disease or disorder wherein the pharmaceutical compositions comprise any one of the agents in Table 1 or a combination of agents; and a pharmaceutically acceptable excipient.
• FIG. 1 is a schematic representation of the ferroptosis pathway.
• FIGS. 2A-2B demonstrates tumor response after in vivo exposure to (1) ferroptosis- inducing compound (A) or (2) ferr optosis-inducing compound (A) + anti-ferroptosis rescue agent (M) after 24 hours.
• FIG. 2A shows cleaved caspase-3 staining. Dashed lines indicate region of drug exposure.
• FIG. 2B shows a graph demonstrating the fractional viability (y-axis) of cells measured in an in vitro assay over time (x-axis) for ferroptosis-inducing compound (A) and for ferroptosis-inducing compound (A) + anti-ferroptosis rescue agent (N).
• FIG. 3 demonstrates tumor response after exposure to (1) ferroptosis-inducing compound (B) or (2) ferroptosis-inducing compound (B) + anti-ferroptosis rescue agent (M) after 24 hours.
• Drug were loaded to achieve concentrations of 1-10 pM for both ferroptosis-inducing compound (A) and anti-ferroptosis rescue agent (M).
• Staining shows cleaved caspase-3. Dashed lines indicate region of drug exposure. Scale bar: 100 micrometers (pm).
• FIG. 4 demonstrates dose-response curves for ferroptosis-inducing compound (A) and ferroptosis-inducing compound (C) on fractional cell viability (y-axis) normalized to DMSO.
• the x-axis shows drug concentration.
• FIGS. 5A-5B demonstrate tumor response after exposure to (1) ferroptosis-inducing compound (C) or (2) ferroptosis-inducing compound (C) + anti-ferroptosis rescue agent (M) after 24 hours. Drug were loaded to achieve concentrations of 1-10 pM for both ferroptosis-inducing compound (C) and anti-ferroptosis rescue agent (M).
• FIG. 5A shows a tumor section stained for cleaved caspase-3. Dashed lines indicate region of drug exposure. Scale bar: 100 micrometers (pm).
• FIG. 5B shows representative H&E images at 18 hours post treatment with (1) ferroptosis- inducing compound (C) or (2) ferroptosis-inducing compound (C) + anti-ferroptosis rescue agent (M) as indicated.
• the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. “About” can be understood as within 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from the context, all numerical values provided herein are modified by the term “about.” Where particular values are described in the application and claims, unless otherwise stated, the term “about” is implicit and in this context means within an acceptable error range for the particular value.
• structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, geometric (or conformational) forms of the structure; for example, the L and D designations for each asymmetric center, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the disclosure.
• adjacent and its grammatical equivalents as used herein refer to right next to or in close proximity to the object of reference.
• the term adjacent in the context of a cell or a tissue can mean without any other cells or tissues in between.
• analog and its grammatical equivalents as used herein refer to a molecule that is not identical, but has analogous structural features.
• An analog of a drug or agent is a drug or agent that is closely related to a reference agent (e.g., an agent provided in Table 1), but whose chemical structure can be different.
• a reference agent e.g., an agent provided in Table 1
• analogues exhibit similar activities to a reference drug or agent, but the activity can be increased or decreased or otherwise improved.
• an analogue form of a compound or drug means that the structure is modified or changed compared to a reference drug.
• active agent refers to an agent that is capable of performing a desired biological activity, for instance killing cells that divide rapidly, agents that modulate cell death, agents that promote cell death, agents that prevent cell death, agents that change cell state, agents that can be used in combination with a ferroptosis inducing agent or chemotherapeutic agent, a priming agent, or a rescue agent.
• anti-cancer agent or “chemotherapeutic agent” and its grammatical equivalents as used herein refer to an agent that is capable of killing cells that divide rapidly (e.g., cancer cells).
• exemplary anti-cancer agents provided herein can be used in combination with a ferroptosis-inducing agent and/or an iron-dependent cell death inducing agent.
• the term “cancer” and its grammatical equivalents as used herein refer to a hyperproliferation of cells whose unique trait — loss of normal controls — results in unregulated growth, lack of differentiation, local tissue invasion, and metastasis.
• the cancer can be any cancer, including but not limited to any one of: acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bladder cancer, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, rectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, fibrosarcoma, gastrointestinal cancer, Hodgkin lympho
• drug resistant cancer and its grammatical equivalents as used herein refers to a cancer that does not respond, or exhibits a decreased response to, one or more chemotherapeutic agents, or one or more apoptotic agents.
• expression and its grammatical equivalents as used herein refers to the biosynthesis of a gene product.
• expression involves transcription of the structural gene into mRNA and the translation of mRNA into one or more polypeptides.
• the term “ferroptosis” refers to a form of cell death involving generation of reactive oxygen species mediated by iron, and characterized by, in part, lipid peroxidation.
• the term “ferroptosis-inducing agent” or “ferroptosis activator” or “ferroptosis inducer” or “ferroptosis- inducing compound” refers to an agent which promotes or activates ferroptosis in a cell.
• hypoproliferative cells and its grammatical equivalents as used herein refers to cells characterized by unwanted cell proliferation, or abnormally high rate or sustained cell division, unrelated or uncoordinated with that of surrounding normal tissue.
• zzz vitro and its grammatical equivalents as used herein refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, etc., rather than within a multi-cellular organism.
• zzz vivo and its grammatical equivalents as used herein refers to events that occur within a multi-cellular organism, such as a non-human animal.
• iron-dependent cell death agent and its grammatical equivalents as used herein refers to an agent which induces, promotes or activates cell death mediated by iron.
• iron-dependent cell death agent is used interchangeably with “ferroptosis-inducing agent”.
• normal cells and its grammatical equivalents as used herein refers to cells that undergo controlled cell division, controlled activation, or quiescent cells.
• compositions and methods useful for treating a disease or condition are also treatment regimens for the therapy of various diseases or conditions such as cancer.
• a treatment regimen can comprise administering a ferroptosis-inducing agent or an iron-dependent cell death agent.
• methods, compositions and uses thereof for inducing ferroptosis in a subject in vivo are (1) methods of characterizing ferroptosis-sensitive cells; (2) cell death-inducing agents including ferroptosis- inducing agents, and chemotherapeutic agents; (3) pharmaceutical compositions; (4) dosing; (5) methods of administration; (6) efficacy; (7) therapeutic applications; and (8) systems.
• Cell death is a cellular process involved in development, cellular homeostasis, and prevention of proliferative diseases such as cancer.
• Programmed cell death can take different forms, such as apoptosis, mitotic catastrophe, necrosis, senescence, and autophagy. While each of these processes ultimately lead to cell death, the pathways and mechanisms appear to be unique, both at the molecular and cellular level.
• Ferroptosis is a non-apoptotic, oxidative form of regulated cell death involving lipid hydroperoxides and the accumulation of lipid peroxide at the cellular plasma membrane.
• Cells undergoing ferroptosis do not display the cellular characteristics or functions associated with apoptosis, the canonical form of cell death. Examples of apoptotic cell features include, e.g., mitochondrial cytochrome c release, caspase activation, and chromatin fragmentation.
• Ferroptosis is also characterized by increased levels of intracellular reactive oxygen species (ROS) which can be prevented by iron chelation and genetic inhibition of cellular iron uptake. Addition of iron, but not by other divalent transition metal ions, can potentiate ferroptosis signaling in cells.
• ROS reactive oxygen species
• Cellular components implicated in and regulating ferroptosis include, among others, cysteine-glutamate antiporter (system Xc), glutathione peroxidase 4 (GPX4), p53, cargo receptor NCOA4, glutathione synthetase (GSH), glutamate-cysteine ligase (GCL).
• system Xc cysteine-glutamate antiporter
• GPX4 glutathione peroxidase 4
• GSH glutathione synthetase
• GCL glutamate-cysteine ligase
• Hyperproliferative cells in a drug-resistant state such as, e.g., drug resistant cancer cells have been found to exhibit a dysregulation in apoptosis cellular pathways.
• Apoptosis-resistant cells can be killed via ferroptosis induction due to their “flammable” ferroptosis-sensitive state.
• Methods of characterizing and markers for characterizing ferroptosis-sensitive cells Provided herein are methods of identifying and characterizing a ferroptosis-sensitive cell in a subject. In some embodiments, the characterizing is performed prior to treatment of a subject with a ferroptosis-inducing agent provided herein.
• Ferroptosis-sensitive cells can be identified by the following properties provided herein: (1) a concentration of selenium greater than a selenium concentration in a corresponding normal cell; (2) a concentration of iron greater than an iron concentration in a corresponding normal cell; (3) a polyunsaturated fatty acid (PUFA) concentration greater than a PUFA concentration in a corresponding normal cell; (4) a peroxidizability index (PI) greater than a PI in a corresponding normal tissue; and/or (5) the expression of one or more markers indicative of a mesenchymal state, among other morphological and histological characteristics. In some embodiments, markers also refer to biomarkers.
• Methods of measuring analyte concentrations of selenium, iron, and PUFAs include, e.g., mass spectrometry, chromatography, immunoassays, immunosorbent assays, absorbance and colorimetric assays, and microwave plasma — atomic emission spectroscopy.
• Methods of measuring markers of a mesenchymal cell state include, e.g., immunoassays, polymerase chain reaction (PCR) assays, and sequencing assays.
• Selenium is a micronutrient that facilitates the synthesis of selenoproteins in a cell. Dietary selenium is found in meat, nuts, cereals, mushrooms, and vegetables. The selenium content in the human body ranges from about 13 milligrams (mg) to 20 mg. Selenium is involved in the cellular process of selenoprotein synthesis and ferroptosis. Selenoproteins are rare proteins that comprise a selenocysteine (Sec) residue in the place of a cysteine.
• Sec selenocysteine
• Non-limiting examples of selenoproteins include GPX1, GPX2, GPX3, GPX4, GPX6, TXNRD1, TXNRD2 (TXRD2), TXNRD3, DIO1, DIO2, DIO3, SEPHS2, SEPS1, SEPPI, SEP 15, SEPN1 (SEl.ENON), SEPX1, SEPW1 (SELENOW), SEPTI, SELH, SELI, SELK, SEEM (SELENOM), SELO, and SELV.
• Selenoproteins exhibit biochemical activities such as oxi doreduction, selenocysteine synthesis, and/or selenium transport.
• GPX4 is a phospholipid hydroperoxidase that catalyzes the reduction of hydrogen peroxide and organic peroxides, thereby protecting cells against membrane lipid peroxidation, and oxidative stress.
• GPX4 is a regulator of the ferroptosis pathway and inhibition of GPX4 induces ferroptotic cell death.
• GPX4 inhibitors act as ferroptosis inducing agents.
• methods of identifying a ferroptosis-sensitive cell in a mammalian tissue by the concentration of selenium comprise measuring the concentration of selenium (Se) in a cell, a plurality of cells, or a mammalian tissue.
• the Se concentration in a cell or the plurality of cells of the mammalian tissue is greater than the Se concentration in cells of healthy tissue by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
• the Se concentration in the plurality of cells of the mammalian tissue is greater than the Se concentration in cells of healthy tissue by l%-10%, 10%-20%, 20%-30%, 30%-40%, 40%-50%, 50%-60%, 60%-70%, 70%-80%, 80%-90%, or 90%-100%.
• methods provided herein comprise administering to a mammal an effective amount of a ferroptosis- inducing agent, wherein a plurality of cells of a mammalian tissue have a selenium concentration greater than the selenium concentration of cells of a normal or healthy tissue; and ferroptosis is induced in the plurality of cells.
• Ferroptosis is an iron-dependent cellular process and ferroptosis-sensitive cells can have increased concentrations of intracellular iron compared with normal cells.
• DFO deferoxamine
• FAC ferric ammonium citrate
• FAC ferric ammonium citrate
• Increased iron uptake in cells can lead to the depletion of glutathione, conceivably due to increased ROS generation which results in ferroptosis induction.
• methods of identifying a ferroptosis-sensitive cell in a mammalian tissue by the concentration of iron comprise measuring the concentration of iron or iron oxide in a cell, a plurality of cells, or a mammalian tissue.
• the ferroptosis-sensitive cells comprise an increased intracellular concentration of iron that is at least about 7 parts per billion (ppb) or more, about 8 ppb or more, about 9 ppb or more, about 10 ppb or more, about 20 ppb or more, about 30 ppb or more, about 40 ppb or more, about 50 ppb or more, about 60 ppb or more, about 70 ppb or more, about 80 ppb or more, about 90 ppb or more, about 100 ppb or more, about 110 ppb or more, about 120 ppb or more, about 130 ppb or more, about 140 ppb or more, about 150 ppb or more, about 160 ppb or more, up to 170 ppb.
• ppb parts per billion
• the ferroptosis-sensitive cells comprise an increased intracellular concentration of iron that is at least about 2 micromolar (pM) or higher, 2.5 pM or higher, 3.0 pM or higher, 4.0 pM or higher, 5.0 pM or higher, up to 10 pM higher than that of normal cells.
• pM micromolar
• the iron concentration in a cell or the plurality of cells of the mammalian tissue is greater than the iron concentration in cells of healthy tissue by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
• the iron concentration in the plurality of cells of the mammalian tissue is greater than the iron concentration in cells of healthy tissue by l%-10%, 10%-20%, 20%-30%, 30%-40%, 40%-50%, 50%-60%, 60%-70%, 70%-80%, 80%-90%, or 90%-100%.
• methods provided herein comprise administering to a mammal an effective amount of a ferroptosis- inducing agent, wherein a plurality of cells of a mammalian tissue of the mammal has an iron concentration greater than the iron concentration of cells of a normal or healthy tissue.
• ferroptosis is induced in the plurality of cells.
• Apoptosis-resistant cells may exhibit a ferroptosis-sensitive state with high levels of polyunsaturated fatty acids (PUFA).
• PUFA polyunsaturated fatty acids
• Apoptosis-resistant cells can be killed via ferroptosis induction due to their “flammable” high-PUFA state.
• the flammable state is defined by high membrane abundance of PUFAs (vs. MUFA, monosaturated fatty acids), which are prone to uncontrolled lipid peroxidation - a radical chain reaction of polyunsaturated fatty acids - that leads to ferroptotic cell death.
• PUFAs are categorized as omega-3 (n-3) and omega-6 (n-6) depending on the location of the last double bond with reference to the terminal methyl end of the molecule.
• Non-limiting examples of PUFAs include: hexadecatrienoic acid (HTA), alpha-linolenic acid (ALA), stearidonic acid (SDA), eicosatrienoic acid (ETE), eicosatetraenoic acid (ETA), eicosapentaenoic acid (EP A, Timnodonic acid), heneicosapentaenoic acid (HP A), docosapentaenoic acid (DPA, Clupanodonic acid), docosahexaenoic acid (DHA, Cervonic acid), tetracosahexaenoic acid (Nisinic acid), tetracosapentaenoic acid, linoleic acid (LA), gamma-lin
• methods of identifying a ferroptosis-sensitive cell in a mammalian tissue by the concentration of PUFAs comprise administering to a mammal an effective amount of a ferroptosis-inducing agent, wherein a plurality of cells of a mammalian tissue has a polyunsaturated fatty acid (PUFA) concentration greater than the PUFA concentration of cells of a normal or healthy tissue; and ferroptosis is induced in the plurality of cells.
• PUFA concentration in the plurality of cells of the mammalian tissue is greater than the PUFA concentration in cells of healthy or non-malignant tissue of the mammal.
• the PUFA concentration in the plurality of cells of the mammalian tissue is greater than the PUFA concentration in cells of healthy tissue by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
• the PUFA concentration in the plurality of cells of the mammalian tissue is greater than the PUFA concentration in cells of healthy tissue by l%-10%, 10%-20%, 20%-30%, 30%-40%, 40%-50%, 50%-60%, 60%-70%, 70%-80%, 80%-90%, or 90%-100%.
• the percent PUFA concentration in cells is measured in mole percent.
• the PUFA concentration in the plurality of cells of the mammalian tissue is greater than a predetermined PUFA concentration.
• the predetermined PUFA concentration can be considered as the PUFA concentration in the plurality of cells when not in a ferroptosis-sensitive state, or when in a ferroptosis-resistant state.
• ferroptosis-sensitivity can increase as PUFA concentration increases, and decrease as PUFA concentration decreases, in a plurality of cells.
• the predetermined PUFA concentration is about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90 mole percent of total lipids.
• the predetermined PUFA concentration is about 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, or 80-90 mole percent of total lipids.
• the predetermined PUFA concentration is about 20 mole percent of total lipids.
• Cell membrane composition must contain a sufficient threshold of polyunsaturated fatty acyl chains to support enzymatic and/or non-enzymatic lipid peroxidation.
• the peroxidizability of polyunsaturated fatty acids (PUFAs) is linearly dependent on the number of doubly allylic positions present in the molecules.
• PI peroxidizability index
• Lipidomic measurements of cellular membrane composition are used to determine the peroxidizability index.
• Cell lines with low PI values ( ⁇ 50) have low sensitivity to ferroptosis-inducing perturbations (e.g., GPX4 inhibition, GSH depletion, addition of pro-oxidant compounds). Cells are more susceptible to undergoing ferroptosis with increasing membrane PI values.
• the ferroptosis sensitivity of cell lines can be modulated by inclusion of fatty acids in the culture medium.
• SFAs Saturated fatty acids
• MUFAs monounsaturated fatty acids
• deuterated PUFAs protect cells from undergoing ferroptosis while the addition of PUFAs increases cell sensitivity to ferroptosis-inducing perturbations.
• Supplementation of cell culture media with exogenous PUFAs can simulate in vivo PUFA concentrations and induce membrane compositions with higher PI values.
• Modulatory profiling assays with fatty acid supplementation and ferroptosis inducers allows for the experimental determination of specific membrane PUFA content and PI values sufficient for ferroptosis for a given cell line.
• the peroxidizability index (PI) of sarcoma and other cancer cells is greater than nonmalignant tissue due to preferential uptake of PUFAs.
• the difference in membrane peroxidizability provides a therapeutic window for ferroptosis induction to selectively target sarcoma cells versus nonmalignant tissue.
• the more peroxidizable membrane state is consistent with observations of higher levels of lipid peroxidative stress in primary bone and soft tissue sarcoma. Addition of exogenous PUFAs can increase oxidative stress in osteogenic sarcoma cells and exhibit selective cytotoxic effects.
• methods of identifying a ferroptosis-sensitive cell in a mammalian tissue by the peroxidizability index comprise administering to a mammal an effective amount of a ferroptosis-inducing agent, wherein a plurality of cells of the mammalian tissue have a PI greater than the PI in cells of normal or healthy tissue; the PI of the plurality of cells is identified, and ferroptosis is induced in the plurality of cells.
• the PI in the plurality of cells of the mammalian tissue is greater than a predetermined PI.
• the predetermined PI is about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150. In some embodiments, the predetermined PI is about 90. In some embodiments, the PI in the plurality of cells of the mammalian tissue is greater than the PI in cells of healthy or non-malignant tissue by about l%-10%, 10%-20%, 20%- 30%, 30%-40%, 40%-50%, 50%-60%, 60%-70%, 70%-80%, 80%-90%, or 90%-100%. (5) Mesenchymal Cell State
• the first cellular signature is the expression of mesenchymal cell markers.
• Ferroptosis-sensitive cells exhibit one or more marker of a mesenchymal cell state.
• Mesenchymal cell state markers that can be used to identify a ferroptosis-sensitive cell include but are not limited to: ZEB1, ACSL4, FADS2, PPARv, Fspl, SLC7A11, SLC3A2, and LPCAT3.
• the second cellular signature of a ferroptosis-sensitive cell is the reduced expression of endothelial cell markers as compared to normal cells.
• Non-limiting examples of endothelial cell markers include: vimentin, E-cadherin, and beta (P)-actin.
• the third cellular signature of a ferroptosis-sensitive cell is the sensitivity to GPX4 knockdown leading to cell death.
• GPX4 dependency is more pronounced in cancer cells adopting a therapy-resistant mesenchymal state as compared to normal mesenchymal cell lines.
• Methods of reducing or silencing GPX4 expression can be achieved, e.g., by CRISPR/Cas9, siRNA or shRNA, among others.
• the methods provided herein comprise administering to a mammal an effective amount of a ferroptosis-inducing agent, wherein a plurality of cells of a mammalian tissue express one or more markers of a mesenchymal cell state; the one or more markers of a mesenchymal cell state are identified, and ferroptosis is induced in the plurality of cells.
• the expression of the mesenchymal cell marker in the plurality of cells of the mammalian tissue is greater than the expression of the mesenchymal cell marker in cells of healthy or non-malignant tissue by about l%-10%, 10%-20%, 20%-30%, 30%-40%, 40%-50%, 50%-60%, 60%-70%, 70%-80%, 80%-90%, or 90%-100%.
• markers can include metabolites of cells.
• the cells are a plurality of cells from a tumor.
• markers are tumor metabolites.
• markers are plasma metabolites.
• markers are detected in vitro.
• markers are detected in vivo.
• Cells undergoing ferroptosis are characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. Histology and immunoassays can be used to determine whether a tissue is cancerous, exhibits hyperplasia, or fibrosis, as well as identify ferroptosis-sensitive cells within a mammalian tissue.
• the cell membrane of cells in a ferroptotic state lack of rupture and blebbing of the plasma membrane normally associated with apoptosis.
• the nuclear size of ferroptotic cells is normal and lacks chromatin condensation.
• the methods provided herein comprise a step of obtaining a biological sample (e.g., blood sample or tissue biopsy) from a subject.
• the methods provided herein further comprise fixing, processing, embedding, sectioning, and staining the biological sample for histological analysis.
• the tissue comprises a histological abnormality.
• the histological abnormality is determined by a tissue biopsy prior to or during the targeted, sustained administration of the ferroptosis-inducing agent to the tissue.
• the histological abnormality is hyperplasia, vascularization/angiogenesis, or fibrosis.
• Hyperplasia is identified by an increased number of cells in a tissue as compared to a normal healthy tissue.
• Vascularization and angiogenesis are identified in a tissue sample by immunoassays for vascular markers, e.g., vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2).
• VEGF vascular endothelial growth factor
• Ang2 angiopoietin-2
• Fibrosis is characterized by abnormal collagen deposits between cells identified in a tissue sample, e.g., by Masson's trichrome, Sirius red, or collagen staining.
• kits for inducing iron-dependent cell death are provided herein.
• methods of inducing iron-dependent cell death in vitro are methods of inducing iron-dependent cell death in vivo.
• methods of inducing irondependent cell death in a tissue in a subject are methods of inducing irondependent cell death in a tissue in a patient in need thereof.
• the irondependent cell death is a cellular process.
• the iron-dependent cell death is ferroptosis. Further provided herein are methods of inducing ferroptosis in a tissue in a subject.
• the method of inducing ferroptosis comprises administration of a therapeutically effective amount of a ferroptosis-inducing agent or a composition or pharmaceutical composition comprising a therapeutically effective amount of a ferroptosis- inducing agent.
• Also provided herein are methods of inducing ferroptosis in a tissue in a subject wherein the methods comprise: (a) sustained administration of a therapeutic amount of a ferroptosis- inducing agent; (b) contacting a tissue in vivo with an effective amount of an iron-dependent cell death agent for a duration of time; and/or (c) contacting a mammalian tissue with a priming agent and then contacting the mammalian tissue in vivo with an effective amount of a ferroptosis- inducing agent for a duration of time.
• Exemplary targets in the ferroptosis pathway are provided in FIG. 1
• the administering induces cell death.
• the administering inhibits or rescues a cell from cell death.
• the administering modulates ferroptosis.
• the administering induces ferroptosis in vivo.
• the administering inhibits ferroptosis in vivo.
• the agent is a ferroptosis-inducing agent.
• the agent is an iron-dependent cell death inducing agent. Agents useful in the induction of ferroptosis in vivo and for the treatment of a disease or disorder are discussed in further detail below.
• the agent is a small molecule, a peptide, or a nucleic acid.
• the ferroptosis-inducing agent is an inhibitor of glutathione peroxidase 4 (GPX4), glutathione synthetase, glutamate-cysteine ligase, phosphoseryl-TRNA Kinase (PSTK), Eukaryotic Elongation Factor Selenocysteine-TRNA Specific (EEFSEC), Selenophosphate Synthetase 2 (SEPHS2), Sep (O-Phosphoserine) TRNA:Sec (Selenocysteine) TRNA Synthase (SEPSECS), or SECIS Binding Protein 2 (SECISBP2).
• GPX4 glutathione peroxidase 4
• PSTK phosphoseryl-TRNA Kinase
• EEFSEC Eukaryotic Elongation Factor Selenocysteine-TRNA Specific
• SEPHS2 Selenophosphat
• the agent is an inhibitor of glutathione peroxidase 4 (GPX4).
• Glutathione peroxidase 4 also known as MCSP; SMDS; GPx-4; PHGPx; snGPx; GSHPx-4; snPHGPx, belongs to the glutathione peroxidase family, members of which catalyze the reduction of hydrogen peroxide, organic hydroperoxides and lipid hydroperoxides, and thereby protect cells against oxidative damage.
• GPX4 activation directly reduces phospholipid hydroperoxide levels in the cellular membrane.
• isozymes of this gene family exist in vertebrates, which vary in cellular location and substrate specificity.
• GPX4 has a high preference for lipid hydroperoxides and protects cells against membrane lipid peroxidation and cell death. This isozyme is also a selenoprotein, containing the rare amino acid selenocysteine (Sec) at its active site.
• Representative human GPX4 cDNA and human GPX4 protein sequences are publicly available from the National Center for Biotechnology Information (NCBI).
• Human glutathione peroxidase 4 peroxidase isoform B precursor (NM_001039847.3 and NP_001034936.1), isoform C (NM_001039848.4 and NP_001034937.1), isoform D (NM_001367832.1 and NP_001354761.1), isoform A precursor (NM_002085.5 and NP_002076.2).
• GPX4 lipid peroxidation-dependent cell death. Cancer cells in a drug-induced, therapy -resistant state have an enhanced dependence on the lipid peroxidase activity of GPX4 to prevent undergoing ferroptotic cell death.
• Lipophilic antioxidants which function as lipophilic radical trapping agents, such as ferrostatin, can rescue cells from GPX4 inhibition-induced ferroptosis, or halt ferroptotic processes. For instance, mesenchymal state GPX4-knockout cells can survive in the presence of ferrostatin, however, when the supply of ferrostatin is terminated, these cells undergo ferroptosis.
• GPX4 inhibition can be rescued by blocking other components of the ferroptosis pathways, such as lipid ROS scavengers (ferrostatin, liproxstatin), lipoxygenase inhibitors, iron chelators and caspase inhibitors, which an apoptotic inhibitor does not rescue. Accordingly, a GPX4 inhibitor can be useful to induce ferroptotic cell death.
• the agent is an inhibitor of glutathione synthetase (GSS).
• Glutathione synthetase also known as GSHS; HEL-S-64p; HEL-S-88n is a homodimer to catalyze the second step of glutathione biosynthesis, which is the ATP-dependent conversion of gamma-L-glutamyl-L-cysteine to glutathione.
• Representative human GSS cDNA and human GSS protein sequences are publicly available from the National Center for Biotechnology Information (NCBI).
• NCBI National Center for Biotechnology Information
• the agent is an inhibitor of glutamate-cysteine ligase (GCL).
• Glutamate-cysteine ligase GCL
• GCL Glutamate-cysteine ligase
• Loss of GCL activity induces ferroptosis in sensitive cells and kills only the most ferroptosis-sensitive cells.
• Representative human GCL cDNA and human GCL protein sequences are publicly available from the National Center for Biotechnology Information (NCBI).
• NCBI National Center for Biotechnology Information
• the agent is an inhibitor of phosphoseryl-TRNA Kinase (PSTK).
• PSTK is an enzyme that recruits selenocysteine, encoded by UGA. Sec is formed in a tRNA-dependent transformation of serine that is attached to tRNA Sec by seryl-tRNA synthetase. PSTK phosphorylates Ser-tRNA Sec to Sep-tRNA Sec which is then converted to Sec-tRNA Sec by Sep-tRNA:Sec-tRNA synthase (SepSecS).
• Representative human PSTK cDNA and human PSTK protein sequences are well-known in the art and are publicly available from the National Center for Biotechnology Information (NCBI).
• the inhibitor is an inhibitor of Eukaryotic Elongation Factor Selenocysteine-TRNA Specific (EEFSEC).
• EEFSEC is also known as selenoprotein translation factor selb.
• Representative human EEFSEC cDNA and human EEFSEC protein sequences are publicly available from the National Center for Biotechnology Information (NCBI) as follows: selenocysteine-specific elongation factor (NM_021937.5 and NP_068756.2), selenocysteine- specific elongation factor isoform X4 (XM_024453695.1 and XP_024309463.1), selenocysteine- specific elongation factor isoform X3 (XM_024453694.1 and XP_024309462.1), selenocysteine- specific elongation factor isoform XI (XM_024453692.1 and XP_024309460.1), selenocysteine- specific elongation factor (
• the agent is an inhibitor of Selenophosphate Synthetase 2 (SEPHS2).
• SEPHS2 Selenophosphate Synthetase 2
• SEPHS2 catalyzes the production of monoselenophosphate (MSP) from selenide and ATP.
• MSP is the selenium donor required for synthesis of selenocysteine (Sec), which is co-translationally incorporated into selenoproteins at in-frame UGA codons that normally signal translation termination.
• This protein is itself a selenoprotein containing a Sec residue at its active site, suggesting the existence of an autoregulatory mechanism.
• SEPHS2 is preferentially expressed in tissues implicated in the synthesis of selenoproteins and in sites of blood cell development. Further, genome-scale cancerdependency profiling identifies selenoprotein synthesis enzymes as targets for ferroptosis induction. Loss of selenoprotein synthesis enzymes induces ferroptosis in sensitive cells. Moreover, Selenophosphate Synthetase 2 (SEPHS2) loss exhibits a novel two-pronged ferroptosis mechanism of action. SEPHS2 loss induced ferroptosis much more quickly than loss of other selenoprotein biosynthetic enzymes. SEPHS2 inhibitors can induce ferroptosis in certain diseases.
• SEPHS2 inhibitors can induce ferroptosis in certain diseases.
• SEPHS2 inhibition For example, aggressive liver cancer is selectively targetable by SEPHS2 inhibition.
• Representative human SEPHS2 cDNA and human SEPHS2 protein sequences are well-known in the art and are publicly available from the National Center for Biotechnology Information (NCBI).
• Selenide, water dikinase 2 (NM_012248.4 and NP_036380.2).
• the agent is an inhibitor of Sep (O-Phosphoserine) TRNA:Sec (Selenocysteine) TRNA Synthase (SEPSECS).
• Sep (O-Phosphoserine) TRNA:Sec (Selenocysteine) TRNA Synthase (SEPSECS) catalyzes the third step in the process of selenocysteine synthesis, the conversion of O-phosphoseryl-tRNA(Sec) to selenocysteinyl- tRNA(Sec).
• Representative human SEPSECS cDNA and human SEPSECS protein sequences are publicly available from the National Center for Biotechnology Information (NCBI) as the follows: O-phosphoseryl-tRNA(Sec) selenium transferase (NM_016955.4 and NP_058651.3), O-phosphoseryl-tRNA(Sec) selenium transferase isoform XI (XM_017008277.1 and XP 016863766.1), O-phosphoseryl-tRNA(Sec) selenium transferase isoform X5 (XM_017008278.1 and XP_016863767.1), O-phosphoseryl-tRNA(Sec) selenium transferase isoform X4 (XM_011513848.1 and XP_011512150.1), O-phosphoseryl-tRNA(Sec) selenium transferase isoform X2 (XM_011513846.2 and XP
• the agent is an inhibitor of SECIS Binding Protein 2 (SECISBP2).
• SECISBP2 is one of the polypeptide components of the machinery involved in co-translational insertion of selenocysteine (Sec) into selenoproteins. Sec is encoded by the UGA codon, which normally signals translation termination. The recoding of UGA as Sec codon requires a Sec insertion sequence (SECIS) element; present in the 3' untranslated regions of eukaryotic selenoprotein mRNAs. This protein specifically binds to the SECIS element, which is stimulated by a Sec-specific translation elongation factor.
• SECISBP2 SECIS Binding Protein 2
• SECISBP2 is one of the polypeptide components of the machinery involved in co-translational insertion of selenocysteine (Sec) into selenoproteins. Sec is encoded by the UGA codon, which normally signals translation termination. The recoding of UGA as Sec codon requires a Sec insertion
• SECISBP2 cDNA and human SECISBP2 protein sequences are publicly available from the National Center for Biotechnology Information (NCBI) as follows: Selenocysteine insertion sequence-binding protein 2 isoform 2 (NM_001282688.2 and NP_001269617.1), selenocysteine insertion sequence-binding protein 2 isoform 3 (NM_001282689.2 and NP_001269618.1), selenocysteine insertion sequence-binding protein 2 isoform 4 (NM_001282690.1 and NP_001269619.1), selenocysteine insertion sequence-binding protein 2 isoform 5 (NM_001354696.2 and NP_001341625.1), selenocysteine insertion sequence-binding protein 2 isoform 6 (NM_001354697.2 and NP_001341626.1), selenocysteine insertion sequence-binding protein 2 isoform 7 (NM_001354698.2 and
• the agent is an inhibitor of Nuclear factor-erythroid factor 2- related factor 2 (NRF2).
• NRF2 is a member of the cap ‘n’ collar (CNC) subfamily of basic region leucine zipper (bZip) transcription factors.
• NRF2 mediates induction of a set of drugmetabolizing enzymes, such as glutathione S-transf erase (GST) and NAD(P)H: quinone oxidoreductase 1 (NQO1), by antioxidants and electrophiles.
• GST glutathione S-transf erase
• NAD(P)H quinone oxidoreductase 1
• NRF2 also regulates GPX4 protein content, intracellular free iron content, and mitochondrial function, thereby modulating ferroptosis.
• NRF2 protein sequences are publicly available from the National Center for Biotechnology Information (NCBI) as the follows: Nrf2 [Homo sapiens , GenBank: AAB32188.1; and transcription factor Nrf2 - human
• the agent is an inhibitor of cystine transporter SLC7A11 (also called xCT).
• SLC7A11 also commonly known as xCT
• SLC7A11 functions to import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in multiple human cancers.
• SLC7A11 (xCT) protein sequences are publicly available from the National Center for Biotechnology Information (NCBI) as the follows: cystine/glutamate transporter [Homo sapiens] NP 055146.1, and cystine/glutamate transporter isoform XI [Homo sapiens] XP 011530104.1.
• the agent is an inhibitor of system Xc.
• System Xc- also named cystine/glutamate antiporter, is an intracellular antioxidant element composed of the light chain SLC7A11 (xCT) and the heavy chain SLC3 A2 (4F2hc) and functions as raw materials for the synthesis of glutathione (GSH).
• cystine/glutamate transporter [Homo sapiens] NP 055146.1, cystine/glutamate transporter isoform XI [Homo sapiens] XP 011530104.1, 4F2 cell-surface antigen heavy chain isoform f [Homo sapiens] NP_001013269.1, 4F2 cell-surface antigen heavy chain isoform c [Homo sapiens] NP_002385.3, 4F2 cell-surface antigen heavy chain isoform b [Homo sapiens] NP 001012680.1, and 4F2 cellsurface antigen heavy chain isoform e [Homo sapiens] NP 001012682.1.
• cystine/glutamate transporter [Homo sapiens] NP 055146.1
• cystine/glutamate transporter isoform XI [Homo sapiens] XP 011530104.1
• 4F2 cell-surface antigen heavy chain isoform f [Homo sapiens]
• the agent is an inhibitor of thioredoxin reductase (TXNRD).
• TRXNRD is involved in reversible S-nitrosylation of cysteines in certain proteins.
• TRXNRD protein sequences are publicly available from the National Center for Biotechnology Information (NCBI) as the follows: thioredoxin reductase [Homo sapiens] AAB35418.1, thioredoxin reductase [Homo sapiens] AAF 15900.1 GI: 6538774, thioredoxin reductase [Homo sapiens] AAD25 167.1, thioredoxin reductase [Homo sapiens] AAD 19597.1, and thioredoxin reductase [Homo sapiens] CAA04503.1.
• the agent is a statin.
• statins include but are not limited to: atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.
• the agent that induces ferroptosis in a tissue is selected from Table 1.
• Exemplary ferroptosis-inducing agents are provided in Table 1 along with their formula, chemical identifiers, and respective target and/or mechanism of action.
• the ferroptosis-inducing agent is selected from the group consisting of: (1S,3R)-RSL3, ML-162, ML-210, JKE-1674, JKE-1716, erastin, jacaric acid, buthionine sulfoximine (BSO), trigonelline, glutamate, sulfasalazine, auranofin, brusatol, sorafenib, sorafenib-d3, sorafenib tosylate, trigonelline, FIN56, FINO2, CIL56, dihydroisotanshinone I, GPX4-IN-3, analogs thereof, derivaties thereof, and salts or pharmaceutidally acceptable salts of any of the foregoing, and derivatives.
• the agent in Table 1 is a pharmaceutically acceptable salt form of the small molecule.
• kits for inducing targeted cell death in a mammalian tissue in vivo comprising: (a) contacting a mammalian tissue with a priming agent; (b) contacting the mammalian tissue in vivo with an effective amount of a ferroptosis-inducing agent for a duration of time of at least 4 hours, when a plurality of cells within the mammalian tissue are responsive to the priming agent as determined by detecting in the mammalian tissue: (i) a plurality of cells comprising a concentration of selenium greater than a selenium concentration in the mammalian tissue prior to contacting with the priming agent; (ii) a plurality of cells comprising a concentration of iron greater than an iron concentration in the mammalian tissue prior to contacting with the priming agent; (iii) a plurality of cells comprising a PUFA concentration greater than a PUFA concentration in the mammalian tissue prior to contacting with the priming
• a priming agent is administered prior to the administration of a ferroptosis-inducing agent provided herein.
• the priming agent is administered in vivo, in vitro, or ex vivo.
• a priming agent is an agent that prepares a subject or tissue for administration of a therapeutically effective dose or amount of a ferroptosis-inducing agent provided herein.
• the priming agent is a ferroptosis-inhibitor.
• the priming agent renders a cell within a tissue as ferroptosis-sensitive.
• the priming agent is a lipophilic antioxidant or radical trapping agent.
• the priming agent is a polyunsaturated fatty acid. In some embodiments, the priming agent is an iron chelator. In some embodiments, the priming agent is a lipid peroxidation inhibitor. In some embodiments, the priming agent modulates blood oxygen levels. In some embodiments the priming agent is a hydroperoxide.
• the priming agent is selected from the group consisting of: liproxstatin-1, ferrostatin-1, deferoxamine (DFO), iron, selenium, vitamin E, erythropoietin, a polyunsaturated fatty acid, N-acetylcysteine, pifithrin-alpha-HBr, and methylnaphthalene-4- propionate endoperoxide (MNPE).
• DFO deferoxamine
• MNPE methylnaphthalene-4- propionate endoperoxide
• the polyunsaturated fatty acid is selected from the group consisting of: hexadecatri enoic acid (HTA), alpha-linolenic acid (ALA), stearidonic acid (SDA), eicosatrienoic acid (ETE), eicosatetraenoic acid (ETA), eicosapentaenoic acid (EP A, Timnodonic acid), heneicosapentaenoic acid (HP A), docosapentaenoic acid (DPA, Clupanodonic acid), docosahexaenoic acid (DHA, Cervonic acid), tetracosahexaenoic acid (Nisinic acid), tetracosapentaenoic acid, linoleic acid (LA), gamma-linolenic acid (GLA), eicosadienoic acid, dihomo-gamma-linolenic acid
• methods provided herein comprise administering any one of the agents listed in Table 2.
• compositions comprising a ferroptosis-inducing agent and a priming agent, rescue agent, or other active agent.
• the pharmaceutical compositions further comprise a chemotherapeutic agent.
• the methods provided herein comprise administering at least one additional treatment to a subject.
• the additional treatment is surgery.
• the additional treatment is radiation therapy.
• the additional treatment is a dietary supplement.
• dietary supplements include: probiotics, selenium, iron, vitamins (e.g., vitamin A, vitamin C, vitamin E), curcumin, fish oils, beta carotene, hydrogen sulfides, fatty acids, methionine, cysteine, homocysteine, taurine, cystine or di-cysteine.
• the dietary supplement is a high-selenium nutritional supplement.
• the additional treatment is an additional therapeutic agent.
• the methods provided herein comprise administering an additional agent in combination with a ferroptosis-inducing agent, an iron-dependent cell death inducing agent, and/or a priming agent provided herein.
• the additional agent is a celldeath inducing agent.
• the additional agent is an anti-cancer agent.
• the anti-cancer agent is a chemotherapeutic agent.
• a chemotherapeutic agent or compound is any agent or compound useful in the treatment of cancer.
• chemotherapeutic cancer agents that can be used in combination with ferroptosis-inducing agents or iron-dependent cell death agents provided herein which include, but are not limited to, mitotic inhibitors (vinca alkaloids). These include vincristine, vinblastine, vindesine and NavelbineTM (vinorelbine, 5’- noranhydroblastine).
• chemotherapeutic cancer agents include topoisomerase I inhibitors, such as camptothecin compounds.
• camptothecin compounds include CamptosarTM (irinotecan HCL), HycamtinTM (topotecan HCL) and other compounds derived from camptothecin and its analogues.
• chemotherapeutic cancer agents that can be used in the methods and compositions disclosed herein are podophyllotoxin derivatives, such as etoposide, teniposide and mitopodozide.
• the present disclosure further encompasses other chemotherapeutic cancer agents known as alkylating agents, which alkylate the genetic material in tumor cells. These include without limitation cisplatin, cyclophosphamide, nitrogen mustard, trimethylene thiophosphoramide, carmustine, busulfan, chlorambucil, belustine, uracil mustard, chlomaphazin, and dacarbazine.
• alkylating agents which alkylate the genetic material in tumor cells.
• alkylating agents include without limitation cisplatin, cyclophosphamide, nitrogen mustard, trimethylene thiophosphoramide, carmustine, busulfan, chlorambucil, belustine, uracil mustard, chlomaphazin, and dacarbazine.
• chemotherapeutic cancer agents examples include cytosine arabinoside, fluorouracil, methotrexate, mercaptopurine, azathioprime, and procarbazine.
• An additional category of chemotherapeutic cancer agents that may be used in the methods and compositions disclosed herein include antibiotics. Examples include without limitation doxorubicin, bleomycin, dactinomycin, daunorubicin, mithramycin, mitomycin, mytomycin C, and daunomycin. There are numerous liposomal formulations commercially available for these compounds.
• the present disclosure further encompasses other chemotherapeutic cancer agents including without limitation anti-tumor antibodies, dacarbazine, azacytidine, amsacrine, melphalan, ifosfamide and mitoxantrone.
• chemotherapeutic cancer agents including without limitation anti-tumor antibodies, dacarbazine, azacytidine, amsacrine, melphalan, ifosfamide and mitoxantrone.
• the disclosed agents provided herein can be administered in combination with other antitumor agents, including cytotoxic/antineoplastic agents and anti-angiogenic agents.
• Cytotoxic/ anti -neoplastic agents can be defined as agents who attack and kill cancer cells.
• Some cytotoxic/ anti -neoplastic agents can be alkylating agents, which alkylate the genetic material in tumor cells, e.g., cis-platin, cyclophosphamide, nitrogen mustard, trimethylene thiophosphoramide, carmustine, busulfan, chlorambucil, belustine, uracil mustard, chlomaphazin, and dacabazine.
• cytotoxic/anti -neoplastic agents can be antimetabolites for tumor cells, e.g., cytosine arabinoside, fluorouracil, methotrexate, mercaptopuirine, azathioprime, and procarbazine.
• Other cytotoxic/anti-neoplastic agents can be antibiotics, e.g., doxorubicin, bleomycin, dactinomycin, daunorubicin, mithramycin, mitomycin, mytomycin C, and daunomycin.
• doxorubicin e.g., doxorubicin, bleomycin, dactinomycin, daunorubicin, mithramycin, mitomycin, mytomycin C, and daunomycin.
• Still other cytotoxic/anti-neoplastic agents can be mitotic inhibitors (vinca alkaloids).
• cytotoxic/anti- neoplastic agents include taxol and its derivatives, L-asparaginase, anti-tumor antibodies, dacarbazine, azacytidine, amsacrine, melphalan, VM-26, ifosfamide, mitoxantrone, and vindesine.
• Anti-angiogenic agents can also be used. Suitable anti -angiogenic agents for use in the disclosed methods and compositions include anti-VEGF antibodies, including humanized and chimeric antibodies, anti-VEGF aptamers and antisense oligonucleotides. Other inhibitors of angiogenesis include angiostatin, endostatin, interferons, interleukin 1 (including a and P) interleukin 12, retinoic acid, and tissue inhibitors of metalloproteinase- 1 and -2. (TIMP-1 and -2). Small molecules, including topoisomerases such as razoxane, a topoisomerase II inhibitor with anti-angiogenic activity, can also be used.
• anti-cancer agents that can be used in combination with the ferroptosis-inducing agents provided herein can include, but are not limited to: acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; avastin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bevacizumab; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetime
• anti-cancer agents include, but are not limited to: 20-epi-l,25 dihydroxyvitamin D3; 5- ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL- TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein- 1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL
• any of the aforementioned chemotherapeutics can be administered at a clinically effective dose or amount.
• a chemotherapeutic can also be administered from about day: -14, -13, -12, -11, -10, -9, -8, -7, -6, - 5, -4, -3, -2, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or up to about day 14 after administration of an agent provided herein.
• a subject can have a refractory cancer that is unresponsive to a chemotherapeutic.
• compositions wherein the pharmaceutical compositions comprise an agent selected from Table 1 or a combination of agents selected from Table 1 and/or Table 2; and a pharmaceutically acceptable excipient, diluent, or carrier.
• the pharmaceutical composition further comprises a cell death inducing agent.
• the pharmaceutical composition further comprises a chemotherapeutic agent.
• pharmaceutical compositions provided herein are in a suspension, optionally a homogeneous suspension.
• pharmaceutical compositions provided herein are in an emulsion form.
• pharmaceutical compositions provided herein comprise a salt form of any one of the agents provided herein.
• the salt is a methanesulfonate salt.
• a pharmaceutical composition comprising a ferroptosis-inducing agent or an iron-dependent cell death agent provided herein.
• agents provided herein are combined with pharmaceutically acceptable salts, excipients, diluents and/or carriers to form a pharmaceutical composition.
• Pharmaceutical salts, excipients, diluents, and carriers may be chosen based on the route of administration, the location of the target issue, and the time course of delivery of the drug.
• a pharmaceutically acceptable carrier or excipient may include solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc., compatible with pharmaceutical administration.
• the pharmaceutical composition is in the form of a solid, semisolid, liquid or gas (aerosol).
• injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
• the sterile injectable preparation may also be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent.
• acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P., and isotonic sodium chloride solution.
• sterile, fixed oils are employed as a solvent or suspending medium.
• any bland fixed oil can be employed including synthetic mono- or diglycerides.
• fatty acids such as oleic acid are used in the preparation of injectables.
• the injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
• Exemplary carriers and excipients can include dextrose, sodium chloride, sucrose, lactose, cellulose, xylitol, sorbitol, malitol, gelatin, polymers, polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), and any combination thereof.
• an excipient such as dextrose or sodium chloride can be at a percent from about 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10%, 10.5%, 11%, 11.5%, 12%, 12.5%, 13%, 13.5%, 14%, 14.5%, or up to about 15%.
• Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
• the encapsulated or unencapsulated conjugate is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as
• Tablets may be either film coated or enteric coated according to methods known in the art.
• Liquid preparations for oral administration can take the form of, for example, solutions, syrups, or suspensions, or they can be presented as a dry product for reconstitution with water or other suitable vehicle before use.
• Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable carriers and additives, for example, suspending agents, e.g., sorbitol syrup, cellulose derivatives, or hydrogenated edible fats; emulsifying agents, for example, lecithin or acacia; non-aqueous vehicles, for example, almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils; and preservatives, for example, methyl or propyl-p- hydroxybenzoates or sorbic acid.
• the preparations can also contain buffer salts, flavoring, coloring, and/or sweetening agents as appropriate. If desired, preparations for oral administration can be suitably formulated to give controlled release of the active compound.
• Formulations suitable for buccal (sublingual) administration include, for example, lozenges containing the active compound in a flavored base, usually sucrose and acacia or tragacanth; and pastilles containing the compound in an inert base such as gelatin and glycerin or sucrose and acacia.
• Ferroptosis-inducing agents provided herein can be formulated as a rectal composition, for example, suppositories or retention enemas, for example, containing conventional suppository bases, for example, cocoa butter or other glycerides, or gel forming agents, such as carbomers.
• compositions also can be administered by controlled release formulations and/or delivery devices (see, e.g., in U.S. Pat. No. 5,733,566).
• Various delivery vehicles are known and can be used to administer ferroptosis-inducing agents provided herein, such as but not limited to, encapsulation in liposomes, microparticles, microcapsules, nanoparticles, vectors, and recombinant cells. Liposomes and/or nanoparticles also can be employed with administration of compositions herein. Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs)). MLVs generally have diameters of from 25 nm to 4 pm.
• MLVs multilamellar vesicles
• Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 angstroms containing an aqueous solution in the core.
• Phospholipids can form a variety of structures other than liposomes when dispersed in water, depending on the molar ratio of lipid to water. At low ratios, the liposomes form. Physical characteristics of liposomes depend on pH, ionic strength and the presence of divalent cations. Liposomes can show low permeability to ionic and polar substances, but at elevated temperatures undergo a phase transition which markedly alters their permeability.
• phase transition involves a change from a closely packed, ordered structure, known as the gel state, to a loosely packed, less-ordered structure, known as the fluid state. This occurs at a characteristic phasetransition temperature and results in an increase in permeability to ions, sugars and drugs.
• Liposomes interact with cells via different mechanisms: endocytosis by phagocytic cells of the reticuloendothelial system such as macrophages and neutrophils; adsorption to the cell surface, either by nonspecific weak hydrophobic or electrostatic forces, or by specific interactions with cell-surface components; fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane, with simultaneous release of liposomal contents into the cytoplasm; and by transfer of liposomal lipids to cellular or subcellular membranes, or vice versa, without any association of the liposome contents. Varying the liposome formulation can alter which mechanism is operative, although more than one can operate at the same time.
• Nanocapsules can generally entrap compounds in a stable and reproducible way. To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 pm) should be designed using polymers able to be degraded in vivo. Biodegradable polyalkyl-cyanoacrylate nanoparticles can also be used as a delivery vehicle.
• Nanoparticle carriers that specifically target a tissue may also be used as a pharmaceutically acceptable carrier.
• the nanoparticle is a gold nanoparticle, a platinum nanoparticle, an iron-oxide nanoparticle, a lipid nanoparticle, a selenium nanoparticle, a tumor-targeting glycol chitosan nanoparticle (CNP), a cathepsin B sensitive nanoparticle, a hyaluronic acid nanoparticle, a paramagnetic nanoparticle, or a polymeric nanoparticle.
• CNP tumor-targeting glycol chitosan nanoparticle
• Suitable pharmaceutical formulations of ferroptosis-inducing agents for transdermal application include an effective amount of an agent with a carrier.
• Carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the subject.
• transdermal devices are in the form of a bandage or patch comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and a means to secure the device to the skin.
• Matrix transdermal formulations may also be used.
• Suitable formulations for topical application are preferably aqueous solutions, ointments, creams or gels well-known in the art.
• the formulations may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
• ferroptosis-inducing agents provided herein are formulated as a depot composition. Such long-acting formulations can be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
• the ferroptosis- inducing agents can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil), ion exchange resins, biodegradable polymers, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
• one or more agent provided herein is formulated as a pharmaceutical food composition (also referred to as a medical food).
• the food composition can be for consumption by a mammal, for example by a human or a non-human mammal.
• Agents provided herein can be formulated as a dietary supplement or a medical food.
• agents provided herein are administered with a food ingredient.
• a food ingredient is any product, composition, or a component of a food known to have or disclosed as having a nutritional effect.
• Food can include various meats (e.g., beef, pork, poultry, fish, etc.), dairy products (e.g., milk, cheese, eggs), fruits, vegetables, cereals, breads, etc., and components thereof.
• Food can be fresh or preserved, e.g., by canning, dehydration, freezing, or smoking.
• Food can be provided in raw, unprepared and/or natural states or in cooked, prepared, and/or combined states.
• the food ingredient is selected from the group consisting of: fat, carbohydrates, protein, fiber, nutritional balancing agent, and mixtures thereof.
• the pharmaceutical food composition provided herein further comprises one or more of a protein or an amino acid.
• the pharmaceutical food composition further comprises adenine, one or more vitamins (e.g., vitamin E), potassium, fatty acids, and/or calcium carbonate.
• the administering is sustained administration of a therapeutically effective amount of a ferroptosis-inducing agent.
• the sustained administration of the ferroptosis-inducing agent comprises providing to a tissue the ferroptosis-inducing agent in an amount sufficient to achieve a distribution of at least about 10 ng/mm 2 within said tissue for a period of at least 4 hours, thereby inducing ferroptosis in the tissue.
• the sustained administration further forms a gradient of a sub-therapeutic amount of the ferroptosis- inducing agent adjacent to an administration site within the tissue.
• sustained administration of the ferroptosis-inducing agent comprises additional administration steps.
• the ferroptosis-inducing agent is administered more than once.
• the administering is via a system provided herein.
• the administering local administration within a tissue.
• the tissue is contacted in vivo with an effective amount of an iron-dependent cell death agent for a duration of time of at least 4 hours.
• the administering comprises contacting a mammalian tissue with a priming agent and contacting the mammalian tissue with an effective amount of a ferroptosis-inducing agent provided herein, wherein the ferroptosis-inducing agent induces targeted cell death in the mammalian tissue in vivo.
• the administering is local administration or systemic administration.
• the administering or contacting step is via intratumoral injection, oral administration, transdermal injection, inhalation, nasal administration, topical administration, vaginal administration, ophthalmic administration, intracerebral administration, rectal administration.
• an agent or combination of agents provided herein are administered as a unit dosage form.
• Many agents can be administered orally as liquids, capsules, tablets, or chewable tablets. Because the oral route is the most convenient and usually the safest and least expensive, it is the one most often used. However, it has limitations because of the way a drug typically moves through the digestive tract. For agents administered orally, absorption may begin in the mouth and stomach. However, most agents are usually absorbed from the small intestine. The drug passes through the intestinal wall and travels to the liver before being transported via the bloodstream to its target site. The intestinal wall and liver chemically alter (metabolize) many agents, decreasing the amount of drug reaching the bloodstream. Consequently, these agents are often given in smaller doses or amounts when injected intravenously to produce the same effect.
• an agent provided herein is formulated for oral administration.
• an agent provided herein is formulated for administration / for use in administration via a subcutaneous, intradermal, intramuscular, inhalation, intravenous, intraperitoneal, intracranial, intrathecal, intratumoral, or oral route.
• a subcutaneous route a needle is inserted into fatty tissue just beneath the skin. After a drug is injected, it then moves into small blood vessels (capillaries) and is carried away by the bloodstream. Alternatively, a drug reaches the bloodstream through the lymphatic vessels.
• the intramuscular route is preferred to the subcutaneous route when larger volumes of a drug product are needed.
• a longer needle is used. Agents are usually injected into the muscle of the upper arm, thigh, or buttock. How quickly the drug is absorbed into the bloodstream depends, in part, on the blood supply to the muscle: The sparser the blood supply, the longer it takes for the drug to be absorbed.
• a needle is inserted directly into a vein.
• a solution containing the drug may be given in a single dose or by continuous infusion.
• the solution is moved by gravity (from a collapsible plastic bag) or, more commonly, by an infusion pump through thin flexible tubing to a tube (catheter) inserted in a vein, usually in the forearm.
• agents or therapeutic regimes are administered as infusions.
• An infusion can take place over a period of time.
• an infusion can be an administration of an agent or therapeutic regime over a period of about 5 minutes to about 5 hours.
• An infusion can take place over a period of about 5 min, 10 min, 20 min, 30 min, 40 min, 50 min, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 4.5 hours, or up to about 5 hours.
• intravenous administration is used to deliver a precise dose quickly and in a well-controlled manner throughout the body. It is also used for irritating solutions, which would cause pain and damage tissues if given by subcutaneous or intramuscular injection.
• An intravenous injection can be more difficult to administer than a subcutaneous or intramuscular injection because inserting a needle or catheter into a vein may be difficult, especially if the person is obese.
• a drug is delivered immediately to the bloodstream and tends to take effect more quickly than when given by any other route. Consequently, health care practitioners closely monitor people who receive an intravenous injection for signs that the drug is working or is causing undesired side effects.
• the effect of a drug given by this route tends to last for a shorter time. Therefore, some agents must be given by continuous infusion to keep their effect constant.
• a needle is inserted between two vertebrae in the lower spine and into the space around the spinal cord. The drug is then injected into the spinal canal. A small amount of local anesthetic is often used to numb the injection site. This route is used when a drug is needed to produce rapid or local effects on the brain, spinal cord, or the layers of tissue covering them (meninges) — for example, to treat infections of these structures.
• the ferroptosis-inducing agent provided herein can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, di chlorotetrafluoroethane, carbon dioxide, or other suitable gas.
• a suitable propellant for example, dichlorodifluoromethane, trichlorofluoromethane, di chlorotetrafluoroethane, carbon dioxide, or other suitable gas.
• the dosage unit can be determined by providing a valve to deliver a metered amount.
• Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base, for example, lactose or starch.
• Agents administered by inhalation through the mouth can be atomized into smaller droplets than those administered by the nasal route, so that the agents can pass through the windpipe (trachea) and into the lungs. How deeply into the lungs the agents go depends on the size of the droplets. Smaller droplets go deeper, which increases the amount of drug absorbed. Inside the lungs, they are absorbed into the bloodstream.
• Agents applied to the skin are usually used for their local effects and thus are most commonly used to treat superficial skin disorders, such as psoriasis, eczema, skin infections (viral, bacterial, and fungal), itching, and dry skin.
• the drug is mixed with inactive substances.
• the formulation may be an ointment, cream, lotion, solution, powder, or gel.
• a treatment regime may be dosed according to a body weight of a subject.
• BMI weight (kg)/ [height (m)] 2 .
• a therapeutic regime can be administered along with a carrier, diluent, or excipient.
• Ferroptosis-inducing agents provided herein can be administered with one or more of a second agent, sequentially, or concurrently, either by the same route or by different routes of administration. When administered sequentially, the time between administrations is selected to benefit, among others, the therapeutic efficacy and/or safety of the combination treatment.
• the agents provided herein can be administered first followed by a second agent, or alternatively, the second agent is administered first followed by the agents of the present disclosure (e.g., ferroptosis-inducing agents of Table 1).
• the time between administrations is about 1 hr, about 2 hr, about 4 hr, about 6 hr, about 12 hr, about 16 hr or about 20 hr. In certain embodiments, the time between administrations is about 1, about 2, about 3, about 4, about 5, about 6, or about 7 more days. In some embodiments, the time between administrations is about 1 week, 2 weeks, 3 weeks, or 4 weeks or more. In some embodiments, the time between administrations is about 1 month or 2 months or more.
• ferroptosis-inducing agents provided herein contact the mammalian tissue for at least about 4 hours, at least about 6 hours, at least about 10 hours, at least about 12 hours, at least about 14 hours, at least about 16 hours, at least about 18 hours, at least about 20 hours, at least about 22 hours, at least about 24 hours, at least about 26 hours, at least about 28 hours, at least about 30 hours, at least about 36 hours, at least about 48 hours, up to 72 hours.
• ferroptosis-inducing agents provided herein contact the mammalian tissue for about 4 hours.
• ferroptosis-inducing agents provided herein contact the mammalian tissue for about 6 hours.
• ferroptosis- inducing agents provided herein contact the mammalian tissue for about 10 hours. In some embodiments, ferroptosis-inducing agents provided herein contact the mammalian tissue for about 12 hours. In some embodiments, ferroptosis-inducing agents provided herein contact the mammalian tissue for about 24 hours. In some embodiments, ferroptosis-inducing agents provided herein contact the mammalian tissue for about 48 hours. In some embodiments, ferroptosis-inducing agents provided herein contact the mammalian tissue for about 72 hours.
• the agent When administered concurrently, the agent can be administered separately, at the same time as the second agent, by the same or different routes, or administered in a single pharmaceutical composition by the same route.
• the amount and frequency of administration of the second agent can used standard dosages and standard administration frequencies used for the particular compound or active agent.
• the methods provided herein comprise administering to a subject an agent or pharmaceutical composition provided herein in an amount effective to induce ferroptosis in a tissue in vivo.
• Agents and pharmaceutical compositions for administering to a subject in need thereof may be formulated in dosage unit form for ease of administration and uniformity of dosage.
• a dosage unit form is a physically discrete unit of a composition provided herein appropriate for a subject to be treated. It will be understood, however, that the total usage of compositions provided herein will be decided by the attending physician within the scope of sound medical judgment.
• the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, such as mice, rabbits, dogs, pigs, or non-human primates.
• the animal model may also be used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
• Therapeutic efficacy and toxicity of compositions provided herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., EDso (the dose is therapeutically effective in 50% of the population) and LDso (the dose is lethal to 50% of the population).
• the dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50.
• Pharmaceutical compositions which exhibit large therapeutic indices may be useful in some embodiments.
• the data obtained from cell culture assays and animal studies may be used in formulating a range of dosage for human use.
• a typical human dose of an agent provided herein may be from about 10 pg/kg body weight/day to 10,000 mg/kg/day.
• the dose of an agent provided herein is from about 0.1 mg/kg to about 1000 mg/kg, from 1 mg/kg to 1000 mg/kg, 1 mg/kg to 800 mg/kg, from about 1 mg/kg to about 700 mg/kg, from about 2 mg/kg to about 500 mg/kg, from about 3 mg/kg to about 400 mg/kg, 4 mg/kg to about 300 mg/kg, or from about 5 mg/kg to about 200 mg/kg.
• the suitable dosages of the agent can be about 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, 250 mg/kg, 300 mg/kg, 400 mg/kg, 500 mg/kg, 600 mg/kg, 700 mg/kg, 800 mg/kg, 900 mg/kg, 1000 mg/kg, 2,000 mg/kg, 3,000 mg/kg, 4,000 mg/kg, 5,000 mg/kg, 6,000 mg/kg, 7,000/mg/kg, 8,000 mg/kg, 9,000 mg/kg, up to 9,600 mg/kg.
• the dose of an agent provided herein is from about 100 mg/kg/day to about 6,400 mg/kg/day four times per day. In some embodiments, the dose of an agent provided herein is from about 50 mg/kg/day to about 25 mg/kg/day. In some embodiments, the dose of an agent provided herein is from about 400 mg/kg/day to about 800 mg/kg/day. In certain embodiments, the dose of the agent can be administered once per day or divided into subdoses and administered in multiple doses, e.g., twice, three times, or four times per day.
• agents provided herein are administered in an amount of at least about 10 nanograms (ng) or more, about 20 ng or more, about 30 ng or more, about 40 ng or more, about 50 ng or more, about 60 ng or more, about 70 ng or more, about 80 ng or more, about 90 ng or more, up to 100 ng.
• the agent is administered in an amount of at least about 1 microgram (pg) or more, at least about 5 pg or more, at least about 10 pg or more, at least about 20 pg or more, at least about 30 pg or more, at least about 40 pg or more, at least about 50 pg or more, at least about 60 pg or more, at least about 70 pg or more, at least about 80 pg or more, at least about 90 pg or more, or an in amount greater than zero pg up to 100 pg.
• pg microgram
• the agent is administered in an amount of at least about 100 pg or more, at least about 500 pg or more, at least about 1000 pg or more, at least about 2000 pg or more, at least about 3000 pg or more, at least about 4000 pg or more, at least about 5000 pg or more, at least about 6000 pg or more, at least about 7000 pg or more, at least about 8000 pg or more, at least about 9000 pg or more, or in an amount greater than zero pg up to 10000 pg.
• the agent is administered in an amount of at least about 10 milligrams (mg) or more, at least about 50 mg or more, at least about 100 mg or more, at least about 200 mg or more, at least about 300 mg or more, at least about 400 mg or more, at least about 500 mg or more, at least about 600 mg or more, at least about 700 mg or more, at least about 800 mg or more, at least about 900 mg or more, a positive amount of greater than zero pg up to 1000 mg.
• mg milligrams
• ferroptosis inducing agents provided herein are administered in an amount of about: 10 ng , 20 ng, 30 ng, 15 ng, 20 ng, 25 ng, 30 ng, 35 ng, 40 ng, 45 ng, 50 ng, 55 ng, 60 ng, 65 ng, 70 ng, 75 ng, 80 ng, 85 ng, about 90 ng, 95 ng, 100 ng, 110 ng, 120 ng, 130 ng, 140 ng, 150 ng, 160 ng, 170 ng, 180 ng, 190 ng, about 200 ng, about 300 ng, about 400 ng, up to 500 ng.
• agents provided herein achieve a distribution within a tissue of at least about 1 ng, about 5 ng, about 10 ng, about 15 ng, about 20 ng, about 25 ng, about 30 ng, about 35 ng, about 40 ng, about 45 ng, about 50 ng, about 55 ng, about 60 ng, about 65 ng, about 70 ng, about 75 ng, about 80 ng, about 85 ng, about 90 ng, about 95 ng, about 100 ng, about 110 ng, about 120 ng, about 130 ng, about 140 ng, about 150 ng, about 160 ng, about 170 ng, about 180 ng, about 190 ng, about 200 ng, about 300 ng, about 400 ng, up to 500 ng.
• agents provide herein can be present in an amount of at least about: 2000 mg, 3000 mg, 4000 mg, 5000 mg, 6000 mg, 7000 mg, 8000 mg, 9000 mg, 10000 mg, 15000 mg, 20000 mg, or 25000 mg.
• agents provided herein are administered at a concentration of at least about 0.1 micromolar (pM) or more, about 1 pM or more, about 2 pM or more, about 3 pM or more, about 4 pM or more, about 5 pM or more, about 6 pM or more, about 7 pM or more, about 8 pM or more, about 9 pM or more, about 10 pM or more, about 15 pM or more, about 20 pM or more, about 25 pM or more, about 30 pM or more, about 35 pM or more, about 40 pM or more, about 45 pM or more, about 50 pM or more, about 55 pM or more, about 60 pM or more, about 65 pM or more, about 70 pM or more, about 75 pM or more, about 80 pM or more, about 85 pM or more, about 90 pM or more, about 95 pM or more, about 100 pM
• agents provided herein are administered at a concentration of at least about 0.1 pM up to about 500 pM. In some embodiments, agents provided herein are administered at a concentration of at least about 1 pM up to 500 pM. In some embodiments, agents provided herein are administered at a concentration of at least about 0.1 pM up to 10 pM. In some embodiments, agents provided herein are administered at a concentration of at least about 1 pM up to 10 pM.
• agents provided herein can be administered at a concentration of at least about: 0.5 pM, 1 pM, 2 pM, 3 pM, 4 pM, 5 pM, 6 pM, 7 pM, 8 pM, 9 pM, 10 pM, 15, pM, 20 pM, 25 pM, 30 pM, 40 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 100 pM, 125 pM, 150 pM, 200 pM, 250 pM, 300 pM, 350 pM, 400 pM, 450 pM, 500 pM, 550 pM, 600 pM, 650 pM, 700 pM, 750 pM, 800 pM, 800 pM, 850 pM, 900 pM, 950 pM, or 1000 pM.
• agents provided herein are administered at a concentration of at least about 10 pM up to 100 pM. In some embodiments, agents provided herein are administered at a concentration of at least about 10 pM up to 200 pM. In some embodiments, agents provided herein are administered at a concentration of at least about 100 pM up to 125 pM. In some embodiments, agents provided herein are administered at a concentration of at least about 100 pM up to 200 pM.
• ferroptosis inducing agents provided herein are administered in an amount of 1 ng/mm 2 or more, about 5 ng/mm 2 or more, about 10 ng/mm 2 or more, about 15 ng/mm 2 or more, about 20 ng/mm 2 or more, about 25 ng/mm 2 or more, about 30 ng/mm 2 or more, about 35 ng/mm 2 or more, about 40 ng/mm 2 or more, about 45 ng/mm 2 or more, about 50 ng/mm 2 or more, about 55 ng/mm 2 or more, about 60 ng/mm 2 or more, about 65 ng/mm 2 or more, about 70 ng/mm 2 or more, about 75 ng/mm 2 or more, about 80 ng/mm 2 or more, about 85 ng/mm 2 or more, about 90 ng/mm 2 or more, about 95 ng/mm 2 or more, about 100 ng/mm 2 or more, about 110 ng/mm 2 or more, about 120 ng/mm 2 or more
• agents provided herein achieve a distribution within a tissue of at least about 1 ng/mm 3 or more, about 5 ng/mm 3 or more, about 10 ng/mm 3 or more, about 15 ng/mm 3 or more, about 20 ng/mm 3 or more, about 25 ng/mm 3 or more, about 30 ng/mm 3 or more, about 35 ng/mm 3 or more, about 40 ng/mm 3 or more, about 45 ng/mm 3 or more, about 50 ng/mm 3 or more, about 55 ng/mm 3 or more, about 60 ng/mm 3 or more, about 65 ng/mm 3 or more, about 70 ng/mm 3 or more, about 75 ng/mm 3 or more, about 80 ng/mm 3 or more, about 85 ng/mm 3 or more, about 90 ng/mm 3 or more, about 95 ng/mm 3 or more, about 100 ng/mm 3 or more, about 110 ng/mm 3 or more, about 120 ng/mm 3 or more, about 130 ng/
• the agent or ferroptosis inducing agent does not include at least one of: sorafenib, sorafenib-d3, a salt of any of the foregoing, or sorafenib tosylate.
• agents, which can be ferroptosis-inducing agents, provided herein are administered intravenously.
• agents, which can be ferroptosis-inducing agents, provided herein are administered intravenously at a concentration of at least about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 60 mg/kg, about 70 mg/kg, about 80 mg/kg, about 90 mg/kg, about 100 mg/kg, about 200 mg/kg, about 300 mg/kg, about 400 mg/kg, about 500 mg/kg, about 600 mg/kg, about 700 mg/kg, about 800 mg/kg, about 900 mg/kg, about 1000 mg/kg, about 1100 mg/kg, about 1200 mg/kg, about 1300 mg/kg, about 1400 mg/kg, about 1500 mg/kg, about 2000 mg/kg, about 2200 mg/kg, about 2400 mg/kg, up to about 2500
• agents, which can be ferroptosis-inducing agents, provided herein are administered intravenously at a concentration of about 25 mg/kg once per day. In some embodiments, agents, which can be ferroptosis-inducing agents, provided herein are administered intravenously at a concentration of about 25 mg/kg twice per day. In some embodiments, agents, which can be ferroptosis-inducing agents, provided herein are administered intravenously at a concentration of about 450 mg/kg/day. In some embodiments, agents, which can be ferroptosis-inducing agents, provided herein are administered intravenously at a concentration of about 650 mg/kg/day.
• agents, which can be ferroptosis-inducing agents, provided herein are administered intravenously at a concentration of about 650 mg/kg/day for 3 continuous days. In some embodiments, agents, which can be ferroptosis-inducing agents, provided herein are administered intravenously at a concentration of about 1300 mg/kg/day. In some embodiments, agents, which can be ferroptosis-inducing agents, provided herein are administered intravenously at a concentration of about 2400 mg/kg/day.
• agents, which can be ferroptosis-inducing agents, provided herein are administered orally.
• agents, which can be ferroptosis-inducing agents, provided herein are administered orally at a concentration of at least about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 60 mg/kg, about 70 mg/kg, about 80 mg/kg, about 90 mg/kg, about 100 mg/kg, about 200 mg/kg, about 300 mg/kg, about 400 mg/kg, about 500 mg/kg, about 600 mg/kg, about 700 mg/kg, about 800 mg/kg, about 900 mg/kg, about 1000 mg/kg, about 1100 mg/kg, about 1200 mg/kg, about 1300 mg/kg, about 1400 mg/kg, about 1500 mg/kg, about 2000 mg/kg, about 2200 mg/kg, about 2400 mg/kg, up to about 2500 mg/
• ferroptosis-inducing agents provided herein are administered orally at a concentration of about 25 mg/kg once per day. In some embodiments, agents, which can be ferroptosis-inducing agents, provided herein are administered orally at a concentration of about 25 mg/kg twice per day. In some embodiments, agents, which can be ferroptosis-inducing agents, provided herein are administered orally at a concentration of about 1300 mg/kg/day. In some embodiments, agents, which can be ferroptosis- inducing agents, provided herein are administered orally at a concentration of about 2400 mg/kg/day.
• the methods provided herein can be characterized by or further comprise measuring the distribution of an agent in a target tissue.
• Distribution of an agent provided herein can be determined by the amount or concentration of the agent within a square millimeter (mm 2 ) or cubic millimeter (mm 3 ) of tissue.
• the tissue may be from about 6 to 7 mm in diameter, 36 to 42mm 2 , or 216 to 294mm 3 .
• the data obtained from animal studies may be used in formulating a range of drug distribution in a mammalian tissue.
• Methods of determining tissue distribution of a drug or agent include, for example, mass spectrometry, chromatography, imaging techniques, and immunoassays.
• the distribution of an agent provided herein can be determined using a system provided herein.
• the tissue is administered a therapeutic amount of a ferroptosis- inducing agent, wherein administration of comprises providing to a tissue the ferroptosis- inducing agent in an amount sufficient to achieve a desired drug distribution.
• administration of comprises providing to a tissue the ferroptosis- inducing agent in an amount sufficient to achieve a desired drug distribution.
• providing the ferroptosis inducing agent, priming agent, rescue agent, or any combination thereof to a tissue administering the ferroptosis inducing agent to a mammal, or a combination of any of the foregoing can be referred to as “exposure” to a ferroptosis inducing agent, priming agent, rescue agent, or any combination thereof.
• agents provided herein achieve a distribution within a tissue of at least about 1 ng/mm 2 or more, about 5 ng/mm 2 or more, about 10 ng/mm 2 or more, about 15 ng/mm 2 or more, about 20 ng/mm 2 or more, about 25 ng/mm 2 or more, about 30 ng/mm 2 or more, about 35 ng/mm 2 or more, about 40 ng/mm 2 or more, about 45 ng/mm 2 or more, about 50 ng/mm 2 or more, about 55 ng/mm 2 or more, about 60 ng/mm 2 or more, about 65 ng/mm 2 or more, about 70 ng/mm 2 or more, about 75 ng/mm 2 or more, about 80 ng/mm 2 or more, about 85 ng/mm 2 or more, about 90 ng/mm 2 or more, about 95 ng/mm 2 or more, about 100 ng/mm 2 or more, about 110 ng/mm 2 or more, about 120 ng/mm 2 or more, about 130 ng/
• agents provided herein achieve a distribution within a tissue of at least about 1 ng/mm 3 or more, about 5 ng/mm 3 or more, about 10 ng/mm 3 or more, about 15 ng/mm 3 or more, about 20 ng/mm 3 or more, about 25 ng/mm 3 or more, about 30 ng/mm 3 or more, about 35 ng/mm 3 or more, about 40 ng/mm 3 or more, about 45 ng/mm 3 or more, about 50 ng/mm 3 or more, about 55 ng/mm 3 or more, about 60 ng/mm 3 or more, about 65 ng/mm 3 or more, about 70 ng/mm 3 or more, about 75 ng/mm 3 or more, about 80 ng/mm 3 or more, about 85 ng/mm 3 or more, about 90 ng/mm 3 or more, about 95 ng/mm 3 or more, about 100 ng/mm 3 or more, about 110 ng/mm 3 or more, about 120 ng/mm 3 or more, about 130 ng/
• the tissue is administered a therapeutic amount of a ferroptosis- inducing agent, wherein administration of comprises providing to a tissue the ferroptosis- inducing agent in an amount sufficient to achieve a desired drug distribution.
• agents provided herein achieve a distribution within a tissue of at least about 1 pM up to 500 pM. In some embodiments, agents provided herein are administered at a concentration of at least about 0.1 pM up to 10 pM. In some embodiments, agents provided herein are administered at a concentration of at least about 1 pM up to 10 pM.
• agents provided herein achieve a distribution within a tissue of at least about: 0.5 pM, 1 pM, 2 pM, 3 pM, 4 pM, 5 pM, 6 pM, 7 pM, 8 pM, 9 pM, 10 pM, 15, pM, 20 pM, 25 pM, 30 pM, 40 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 100 pM, 125 pM, 150 pM, 200 pM, 250 pM, 300 pM, 350 pM, 400 pM, 450 pM, 500 pM, 550 pM, 600 pM, 650 pM, 700 pM, 750 pM, 800 pM, 800 pM, 850 pM, 900 pM, 950 pM, or 1000 pM.
• agents provided herein are administered at a concentration of at least about 10 pM up to 100 pM. In some embodiments, agents provided herein achieve a distribution within a tissue of at least about 10 pM up to 200 pM. In some embodiments, agents provided herein are administered at a concentration of at least about 100 pM up to 125 pM. In some embodiments, agents provided herein are administered at a concentration of at least about 100 pM up to 200 pM. In some embodiments, agents, which can be ferroptosis-inducing agents, provided herein are administered at least about once per day, twice per day, three times per day, four times per day, or five times per day.
• agents which can be ferroptosis-inducing agents, are administered at least about every week, at least about every 2 weeks, or at least about every 3 weeks.
• the amount of drug administered depends on the size of the tissue, the type of disease being treated, and the type of administration (e.g., local administration to a tissue in vivo using a system provided herein). Effective doses or amounts will vary, depending on the types of diseases treated, route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatments.
• ferroptosis-inducing agents provided herein have a sustained administration of: at least about 1 hour, at least about 2 hours, at least about 4 hours, at least about 6 hours, at least about 10 hours, at least about 12 hours, at least about 14 hours, at least about 16 hours, at least about 18 hours, at least about 20 hours, at least about 22 hours, at least about 24 hours, at least about 26 hours, at least about 28 hours, at least about 30 hours, at least about 36 hours, at least about 48 hours, or up to 72 hours.
• ferroptosis- inducing agents provided herein have a sustained administration of about 4 hours.
• ferroptosis-inducing agents provided herein have a sustained administration of about 6 hours.
• ferroptosis-inducing agents provided herein have a sustained administration of about 10 hours. In some embodiments, ferroptosis-inducing agents provided herein have a sustained administration of about 12 hours. In some embodiments, ferroptosis-inducing agents provided herein have a sustained administration of about 24 hours. In some embodiments, ferroptosis-inducing agents provided herein have a sustained administration of about 48 hours. In some embodiments, ferroptosis-inducing agents provided herein have a sustained administration of about 72 hours.
• sustained administration of a ferroptosis-inducing agent is in the amount of a subtherapeutic amount.
• a subtherapeutic amount is an amount that does not completely alleviate a disease or condition.
• a subtherapeutic amount is an amount that is less than a therapeutic amount for treating a disease or condition.
• the administration of a ferroptosis-inducing agent can initially be at a subtherapeutic amount which is subsequently increased to a therapeutic amount.
• the subtherapeutic amount is detected adjacent or proximal to an administration site within a tissue.
• the amount of a ferroptosis inducing agent is measured using metabolomics techniques.
• the amount of a ferroptosis inducing agent is measured using by matrix assisted laser desorption/ionization imaging mass spectrometry (MALDI-MS). In some embodiments, the amount of a ferroptosis inducing agent is measured using proteomics techniques. In some embodiments, the amount of a ferroptosis inducing agent is measured using liquid chromatography mass spectrometry (LCMS). In some embodiments, the amount of a ferroptosis inducing agent is measured using several analytic methods and/or tools.
• MALDI-MS matrix assisted laser desorption/ionization imaging mass spectrometry
• proteomics techniques In some embodiments, the amount of a ferroptosis inducing agent is measured using proteomics techniques. In some embodiments, the amount of a ferroptosis inducing agent is measured using liquid chromatography mass spectrometry (LCMS). In some embodiments, the amount of a ferroptosis inducing agent is measured using several analytic methods and/or tools.
• Therapeutic efficacy of an agent and/or pharmaceutical composition provided herein may be determined by evaluating and comparing patient symptoms and quality of life pre- and postadministration. Such methods apply irrespective of the mode of administration.
• pre-administration refers to evaluating patient symptoms and quality of life prior to onset of therapy and post-administration refers to evaluating patient symptoms and quality of life at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 weeks after onset of therapy.
• the post-administration evaluating is performed about 2-8, 2-6, 4-6, or 4 weeks after onset of therapy.
• patient symptoms e.g., symptoms related to cancer, fibrosis, or autoimmune disease
• quality of life pre- and postadministration are evaluated clinically and by questionnaire assessment.
• the agents and methods provided herein can be used to reduce cancer cell proliferation or survival in vivo or in vitro. Methods of evaluating tumor progression or cell proliferation are known in the art. In some embodiments, overall response is assessed from time-point response assessments (based on tumor burden) as follows:
• CR Complete Response
• PR Partial Response
• PD Progressive Disease
• Stable Disease Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
• an in vitro cell proliferation assay is used to assess the efficacy of a one or more ferroptosis-inducing agents provided herein.
• the compositions and methods provided herein result in a reduction in the proliferation or survival of a plurality of cells. For example, after treatment with one or more of the agents provided herein, cell proliferation or survival is reduced by 5% or greater (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater) relative to cell proliferation or survival prior to treatment.
• animal models are used to assess the efficacy of a one or more ferroptosis-inducing agents provided herein in vivo.
• the ferroptosis-inducing agents and methods provided herein can result in a reduction in size or volume of a hyperproliferating tissue (e.g., a tumor).
• tissue size is reduced by 5% or greater (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater) relative to its size prior to treatment.
• Size of a tissue e.g., a tumor
• the size of a tissue may be measured as a diameter of the tumor or by any reproducible means of measurement.
• Ferroptosis inhibitors may be used to determine the efficacy of a particular test agent (also referred to herein as an active agent) for inducing ferroptosis in a tissue.
• a particular test agent also referred to herein as an active agent
• the combination of a ferroptosis inducer paired with a ferroptosis inhibitor can be used to determine whether the test agent targets a protein or nucleic acid involved in the ferroptosis pathway (see FIG. 1).
• the test agent is referred to as a priming agent.
• the test agent is referred to as a rescue agent.
• the test agent is administered concurrently, consecutively, or after administration of the ferroptosis inducing agent.
• a method of rescuing a cell or plurality of cells from cell death and/or ferroptosis in vivo comprising: administering to a subject a ferroptosis inhibitor.
• the method further comprises administering a ferroptosis-inducing agent.
• a method of screening a plurality of cells in a tissue for ferroptosis-sensitivity the method comprising: contacting the tissue with a ferroptosis-inducing agent and a ferroptosis inhibitor; and measuring one or more parameters indicative of ferroptosis.
• the parameter is the occurrence and/or measurement of a gene product. In some embodiments the parameter is the occurrence and/or measurement of a tumor metabolite. In some embodiments the parameter is the occurrence and/or measurement of a plasma metabolite.
• the ferroptosis-inducing agent is an agent in Table 1 or a test agent. In some embodiments, the ferroptosis inhibitor is any agent listed in Table 2. In some embodiments, the ferroptosis inhibitor is liproxstatin-1.
• the one or more parameters indicative of ferroptosis are PUFA concentration, PI index, modulation of mesenchymal cell state marker expression, or modulation of iron or selenium concentration.
• the screening method provided herein can be readily scaled for high throughput analyses, that permit evaluation or prediction of the ferroptosis-inducing activity of test agents. Similarly, the screening method can be performed in animal models as discussed above in the presence and absence of a ferroptosis inhibitor.
• Treating a disease or disorder can further result in a decrease in number of hyperproliferative tissues (e.g., tumors).
• hyperproliferative tissue or tumor number is reduced by 5% or greater (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater) relative to number prior to treatment.
• Number of tumors may be measured by any reproducible means of measurement. The number of tumors may be measured by counting tumors visible to the naked eye or at a specified magnification (e.g, 2x, 3x, 4x, 5x, lOx, or 50x).
• methods and ferroptosis-inducing agents provided herein increase the number or activity of leukocytes in a tumor microenvironment.
• the leukocytes specifically target cancer cells with a high PUFA concentration as compared with normal cells.
• Treating cancer can result in a decrease in number of metastatic nodules in other tissues or organs distant from the primary tumor site.
• the number of metastatic nodules is reduced by 5% or greater (e.g, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater) relative to number prior to treatment.
• the number of metastatic nodules may be measured by any reproducible means of measurement.
• the number of metastatic nodules may be measured by counting metastatic nodules visible to the naked eye or at a specified magnification (e.g., 2x, lOx, or 50x).
• Treating a disease or disorder can result in an increase in average survival time of a population of subjects treated according to the present invention in comparison to a population of untreated subjects.
• the average survival time is increased by more than 30 days (more than 60 days, 90 days, 120 days or longer).
• An increase in average survival time of a population may be measured by any reproducible means.
• An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with the compound of the invention.
• An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with the compound of the invention.
• Treating a disease or disorder can also result in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population.
• the mortality rate is decreased by more than 2% (e.g., more than 5%, 10%, 25%, or greater).
• a decrease in the mortality rate of a population of treated subjects may be measured by any reproducible means, for example, by calculating for a population the average number of disease- related deaths per unit time following initiation of treatment with the compound of the invention.
• a decrease in the mortality rate of a population may also be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following completion of a first round of treatment with a ferroptosis-inducing agent.
• Treating a disease or disorder can also result in a decrease in at least one symptom associated with the disease, disorder, or condition.
• the methods provided herein reduce at least one symptom of a disease or disorder by at least 10%, 20%, 30%, 40%, 50%, 70%, 80%, 90% or greater relative to number prior to treatment.
• cell death can be detected at a time point at or after contacting the mammalian tissue with the ferroptosis-inducing agent.
• the methods provided herein increase cell death by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater relative to number prior to treatment.
• methods of treating a disease or a disorder in a subject In some embodiments, the subject has, is suspected of having, or is at risk of developing a hyperproliferative disease or condition. In some embodiments, methods provided herein further comprise a step of obtaining a biopsy of the tissue for histological analysis. In some embodiments, the tissue comprises a histological abnormality, wherein the histological abnormality is hyperplasia or fibrosis.
• the subject has, is suspected of having, or is at risk of developing a disease or condition associated with abnormal angiogenesis or vascularization.
• Diseases or conditions associated with abnormal angiogenesis or vascularization can include but are not limited to: ocular neovascularization, macular degeneration, retinopathy, sarcomas, polycystic kidney disease, benign hyperplasias, leiomyomas, adenomas, lipomas, hemangiomas, fibromas, vascular occlusion, restenosis, atherosclerosis, pre-neoplastic lesions, carcinoma in situ, and cancer.
• the subject has, is suspected of having, or is at risk of developing an autoimmune disease.
• Non-limiting examples of relevant autoimmune diseases include: rheumatoid arthritis, inflammatory bowel disease, osteoarthritis, oral hairy leukoplakia, and psoriasis.
• the subject has, is suspected of having, or is at risk of developing fibrosis.
• Non-limiting examples of diseases and conditions associated with fibrosis include: keloid scars, hypertrophic scars, systemic sclerosis, pulmonary arterial hypertension, cardiac fibrosis, hypertrophic cardiomyopathy valvular disease, myelofibrosis, myelodysplastic syndrome, chronic myelogenous leukemia, portal hypertension, hepatocellular carcinoma, retroperitoneal fibrosis, intestinal fibrosis, enteropathies, subretinal fibrosis, epiretinal fibrosis, cystic fibrosis, emphysema, pancreatic fibrosis, chronic pancreatitis, duct obstruction, arthrofibrosis, renal fibrosis, nephrogenic systemic fibrosis, renal anemia, chronic kidney disease, Dupuytren’s disease, Ledderhose disease (plantar fibromatosis), primary biliary cholangitis (PBC), non-alcoholic steatohepatitis (NASH), scler
• the subject has, is suspected of having, or is at risk of developing cancer.
• the subject has a benign tumor.
• the subject has a pre-cancerous lesion.
• the subject has a basal cell carcinoma (BCC) or a squamous cell carcinoma (SCC).
• BCC basal cell carcinoma
• SCC squamous cell carcinoma
• the subject has a metastatic tumor.
• the cancer is a solid cancer or a blood cancer.
• the blood cancer is a leukemia or a lymphoma.
• the subject has a solid tumor.
• the solid tumor is a carcinoma, a melanoma, or a sarcoma.
• the melanoma is a dedifferentiated melanoma or amelanotic melanoma.
• the subject has a melanoma with a B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation.
• the subject has a sarcoma with a Kirsten rat sarcoma (KRAS) mutation.
• the sarcoma is a soft tissue sarcoma.
• the sarcoma is leiomyosarcoma.
• the carcinoma is a colon adenocarcinoma.
• Non-limiting examples of cancer that can be treated with an agent provided herein include: acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer (e.g., cervical adenocarcino
• liver cancer e.g., hepatocellular cancer (HCC), malignant hepatoma
• lung cancer e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung
• leiomyosarcoma LMS
• mastocytosis e.g., systemic mastocytosis
• muscle cancer myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), angiogenic myeloid metaplasia (AMM) a.k.a.
• myelofibrosis MF
• chronic idiopathic myelofibrosis chronic myelocytic leukemia (CIVIL), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES); neuroblastoma; neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis); neuroendocrine cancer (e.g., gastroenteropancreatic neuroendocrine tumor (GEP NET), carcinoid tumor); osteosarcoma (e.g., bone cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), islet cell tumors); penile cancer (e.g.
• tissue comprises different cell types.
• the tissue comprises a heterogeneous population of cells, wherein the heterogeneous population of cells comprises at least one of precancerous cells and non-cancerous cells.
• the tissue comprises a heterogeneous population of cells, wherein the heterogeneous population of cells comprises a population of immune cells.
• a method of inducing immune cell recruitment to a tumor comprising: administering to a subject a ferroptosis-inducing agent provided herein by any of the methods provided herein.
• the administering is sustained administration for at least about 10 hours, thereby recruiting immune cells to the tumor site.
• the immune cells are leukocytes.
• the immune cells are monocytes.
• following contact with a mammalian tissue or administration of a ferroptosis-inducing agent immune cell recruitment can be detected at a time point at or after contacting the mammalian tissue with the ferroptosis-inducing agent.
• the administering reduces the size of the tumor and/or increases the number of leukocytes within the tumor.
• systems for the delivery of a ferroptosis-inducing agent or an irondependent cell death inducing agent provided herein.
• systems for inducing in vivo ferroptosis comprising: an implantable microdevice configured for localized administration to a tissue comprising: (a) a cylindrical support structure having at least one microwell on a surface of or formed within the support structure; (b) a microdose of a ferroptosis-inducing agent in the at least one microwell; and (c) a compound release mechanism for sustained administration for controlling a release of the ferroptosis-inducing agent from the microwell, wherein the microdose of the ferroptosis-inducing agent forms a gradient of a sub- therapeutic amount of the ferroptosis-inducing agent to an administration site within the tissue for a duration of time of at least 4 hours, wherein the microdevice is configured to permit implantation into the tissue using a catheter, cannula or biopsy
• systems for identifying ferroptosis induction in an animal model comprising: (a) an animal model comprising a target tissue of interest; (b) a microdevice configured to permit implantation into a tissue in the animal model using a catheter, cannula or biopsy needle comprising: (i) at least one microwell containing one or more active agents; (ii) a micro-dose of the one or more active agents in the at least one microwell; and (iii) a compound release mechanism comprising a polymeric matrix for controlling the release of the one or more active agents from the microwell into the tissue; wherein the system measures an outcome of ferroptosis induction in the animal model after administration of the one or more active agents into the tissue relative to a baseline tissue without administration of the one or more active agents, and identifying one or more active agents induces ferroptosis in the tissue.
• systems for screening for ferroptosis-induced cell death in vivo comprising: (a) an animal model comprising a target tissue of interest; (b) a microdevice configured to permit implantation into a tissue in the animal model using a catheter, cannula or biopsy needle comprising: (i) at least one microwell containing one or more active agents; (ii) at least one microwell containing one or more ferroptosis inhibitors; (ii) a micro-dose of the one or more active agents; and/or one or more ferroptosis inhibitors in the at least one microwell; and (iii) a compound release mechanism comprising a polymeric matrix for controlling the release of the one or more active agents from the microwell into the tissue; wherein the system measures an outcome of ferroptosis induction in the animal model after administration of the one or more active agents into the tissue relative to a baseline tissue without administration of the one or more active agents, wherein the system measures an outcome of ferroptosis
• the systems provided herein generally include multiple microwells arranged on or within a support structure.
• the microwells contain one or more active agents, alone or in combination, in one or more dosages and/or release pharmacokinetics.
• the devices are configured to deliver the microdose amounts so as to virtually eliminate overlap in the tissue of active agents released from different microwells.
• the devices are configured to facilitate implantation and retrieval in a target tissue.
• the device has a cylindrical shape, having symmetrical wells on the outside of the device, each well containing one or more drugs, at one or more concentrations. The device is sized to permit placement using a catheter, cannula, or stylet.
• the device has a guidewire to assist in placement and retrieval.
• the device may also include features that assist in maintaining spatial stability of tissue excised with the device, such as fins or stabilizers that can be expanded from the device prior to or at the time of removal.
• the device has fiber optics, sensors and/or interactive features such as remote accessibility (such as Wi-Fi) to provide for in situ retrieval of information and modification of device release properties.
• the fiber optics and/or sensors are individually accessible to discrete wells.
• the systems provided herein are formed of biocompatible silicon, metal, ceramic or polymers. They may include materials such as radiopaque materials or materials that can be imaged using ultrasound or MRI. They can be manufactured using techniques such as deep ion etching, nano imprint lithography, micromachining, laser etching, three-dimensional printing or stereolithography. Drug can be loaded by injection of a solution or suspension into the wells followed by solvent removal by drying, evaporation, or lyophilization, or by placement of drug in tablet or particulate form into the wells. In a preferred embodiment, drugs are loaded on top of hydrogel pads within the microwells. The hydrogel pads expand during implantation to deliver the drugs to the surrounding tissue.
• Drug release pharmacokinetics are a function of drug solubility, excipients, dimensions of the wells, and tissue into which the device is implanted (with greater rate of release into more highly vascularized tissue, than into less vascular tissue).
• the systems provided herein are implanted directly into a solid tumor or tissue to be biopsied. Upon implantation, the systems provided herein locally release an array of active agents in microdoses. Subsequent analysis of tumor response to the array of active agents can be used to identify particular drugs, combinations of drugs, and/or dosages that are effective for treating a solid tumor in a patient.
• the microassay device By locally delivering microdoses of an array of drugs, the microassay device can be used to test patients for response to large range of regimens, without inducing systemic toxicities, quickly and under actual physiological conditions. These data are used, optionally in combination with genomic data, to accurately predict systemic drug response.
• the systems provided herein can administer an agent provided herein according to any of the methods provided herein.
• a system provided herein can be used to deliver a microdose of an agent to a tissue in vivo.
• the systems described herein can provide sustained administration of a therapeutic amount of a ferroptosis-inducing agent to a tissue, wherein the sustained administration of said therapeutic amount comprises providing to said tissue the ferroptosis-inducing agent in an amount sufficient to achieve a distribution of at least about 10 ng/mm 2 within said tissue for a period of at least 4 hours, thereby inducing ferroptosis in the tissue.
• the distribution or presence of a ferroptosis- inducing agent within a tissue occurs or is resident for a period of at least about: 1, 2, 3, 4, 5, 6, 12, 24, 36, 48, 72 hours.
• the sustained administration further forms a gradient of a sub-therapeutic amount of the ferroptosis-inducing agent adjacent to the administration site within the tissue.
• the sustained administration of a therapeutic amount of a ferroptosis-inducing agent is at least 10 hours.
• the therapeutic amount of a ferroptosis-inducing agent is a concentration of at least about 1 pM up to 10 pM.
• a system provided herein is implanted into a tumor. In some embodiments, the system delivers one or more a ferroptosis-inducing agents to a tumor.
• the methods comprise: sustained administration of a therapeutic amount of a ferroptosis-inducing agent to a tissue, wherein the sustained administration of said therapeutic amount comprises providing to said tissue the ferroptosis-inducing agent in an amount sufficient to achieve a distribution of at least about 10 ng/mm 2 within said tissue for a period of at least 4 hours, thereby inducing ferroptosis in the tissue.
• the sustained administration further forms a gradient of a sub-therapeutic amount of the ferroptosis-inducing agent adjacent to an administration site within the tissue.
• the sustained administration of the ferroptosis-inducing agent further comprises additional administration steps.
• the tissue comprises a heterogeneous population of cells, wherein the heterogeneous population of cells comprises at least one of precancerous cells or non-cancerous cells, or a combination thereof.
• the tissue comprises a heterogeneous population of cells, wherein the heterogeneous population of cells comprises a population of immune cells.
• the tissue comprises a heterogeneous population of cells, wherein the heterogeneous population of cells comprises a first population of cells comprising a greater concentration of selenium or iron compared to a predetermined concentration of selenium or iron; and a second population of cells comprising said predetermined level of selenium or iron.
• the tissue comprises a homogenous population of cells.
• the tissue comprises a plurality of cancer cells.
• the tissue comprises a plurality of cells expressing one or more markers indicative of a mesenchymal state.
• the one or more markers are selected from the group consisting of: ZEB1, ACSL4, FADS2, PPARy, Fspl, SLC7A11, SLC3A2, and LPCAT3.
• the tissue comprises a plurality of cells that have a reduction in the expression of one or more endothelial cell markers.
• the endothelial cell marker is vimentin, E-cadherin, or beta (P)-actin.
• the tissue comprises a histological abnormality.
• the histological abnormality is determined by a tissue biopsy of the tissue prior to, or during the targeted, sustained administration of the ferroptosis-inducing agent to the tissue. Further provided herein are methods, wherein the histological abnormality is hyperplasia or fibrosis. Further provided herein are methods, wherein the tissue comprises a plurality of cells with a polyunsaturated fatty acids (PUFA) concentration greater than a PUFA concentration in cells of a normal tissue. Further provided herein are methods, wherein the PUFA concentration in the plurality of cells is greater than a predetermined PUFA concentration.
• PUFA polyunsaturated fatty acids
• the tissue comprises a plurality of cells with a peroxidizability index (PI) greater than the PI in cells of normal or healthy tissue; and ferroptosis is induced in the plurality of cells.
• PI peroxidizability index
• ferroptosis-inducing agent is an inhibitor of glutathione peroxidase 4 (GPX4), glutathione synthetase, glutamate-cysteine ligase, phosphoseryl-TRNA Kinase (PSTK), Eukaryotic Elongation Factor Selenocysteine-TRNA Specific (EEFSEC), Selenophosphate Synthetase 2 (SEPHS2), Sep (O-Phosphoserine) TRNA:Sec (Selenocysteine) TRNA Synthase (SEPSECS), or SECIS Binding Protein 2 (SECISBP2).
• GPX4 glutathione peroxidase 4
• glutathione synthetase glutamate-cysteine ligase
• PSTK phosphoseryl-TRNA Kinase
• EEFSEC Eukaryotic Elongation Factor Selenocysteine-TRNA Specific
• SEPHS2 Selenophosphate Syn
• ferroptosis-inducing agent is a small molecule, a peptide, or a nucleic acid. Further provided herein are methods, wherein the ferroptosis-inducing agent is any one or more of the agents in Table 1.
• ferroptosis- inducing agent is selected from Table 1, for instance, from the group consisting of: (1S,3R)- RSL3, ML- 162, ML-210, JKE-1674, JKE-1716, erastin, jacaric acid, buthionine sulfoximine (BSO), trigonelline, glutamate, sulfasalazine, auranofin, brusatol, sorafenib, sorafenib-d3, sorafenib tosylate, trigonelline, FIN56, FINCh, CIL56, dihydroisotanshinone I, GPX4-IN-3, analogs, and derivatives thereof, or a pharmaceutically acceptable salt of any of the foregoing.
• ferroptosis-inducing agent contacts the tissue at a localized site for about 1 hour. Further provided herein are methods, wherein the ferroptosis- inducing agent contacts the tissue at a localized site for about 2 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the tissue at a localized site for about 3 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the tissue at a localized site for about 4 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the tissue at a localized site for about 5 hours.
• ferroptosis-inducing agent contacts the tissue at a localized site for about 6 hours. Further provided herein are methods, wherein the ferroptosis- inducing agent contacts the tissue at a localized site for about 6 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the tissue at a localized site for about 10 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the tissue at a localized site for about 24 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the tissue at a localized site for about 48 hours.
• ferroptosis-inducing agent contacts the tissue at a localized site for about 72 hours. Further provided herein are methods, wherein the ferroptosis- inducing agent is administered at a concentration of at least about 0.1 pM to 10 pM. Further provided herein are methods, wherein the tissue is resistant to treatment with an anti-apoptotic agent. Further provided herein are methods, wherein the tissue is a tumor or a tissue comprising a plurality of cancer cells. Further provided herein are methods, wherein the cancer is a solid tumor or a blood cancer. Further provided herein are methods, wherein the blood cancer is a leukemia or a lymphoma.
• the solid tumor is a carcinoma, a melanoma, or a sarcoma.
• the melanoma is a dedifferentiated melanoma or amelanotic melanoma.
• the subject has or is at risk of developing cancer.
• the cancer is a: breast cancer, brain cancer, pancreatic cancer, prostate cancer, skin cancer, bladder cancer, lung cancer, liver cancer, ovarian cancer, renal cancer, endometrial cancer, colorectal cancer, gastric cancer, skin cancer, head and neck cancer, or thyroid cancer.
• the cancer is acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (e.g., meningioma, glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcino
• liver cancer e.g., hepatocellular cancer (HCC), malignant hepatoma
• lung cancer e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung
• leiomyosarcoma LMS
• mastocytosis e.g., systemic mastocytosis
• muscle cancer myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV), essential thrombocytosis (ET), angiogenic myeloid metaplasia (AMM) a.k.a.
• myelofibrosis MF
• chronic idiopathic myelofibrosis chronic myelocytic leukemia (CIVIL), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES); neuroblastoma; neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis); neuroendocrine cancer (e.g., gastroenteropancreatic neuroendocrine tumor (GEP NET), carcinoid tumor); osteosarcoma (e.g., bone cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors); penile cancer (e.g.
• the methods comprise: contacting a tissue in vivo with an effective amount of an iron-dependent cell death agent for a duration of time of at least 4 hours, wherein the tissue comprises one or more of: (a) a plurality of cells comprising a concentration of selenium greater than a selenium concentration in a corresponding normal tissue; (b) a plurality of cells comprising a concentration of iron greater than an iron concentration in a corresponding normal tissue; (c) a plurality of cells comprising a PUFA concentration greater than a PUFA concentration in a corresponding normal tissue; (d) a plurality of cells expressing one or more markers indicative of a mesenchymal state; and/or (e) a plurality of cells comprising a peroxidizability index (PI) greater than a PI in a corresponding normal tissue, wherein the effective amount of the iron-dependent cell death agent has a concentration of:
• the iron-dependent cell death agent is any one of the agents listed in Table 1.
• the ferroptosis-inducing agent is selected from Table 1, for instance, from the group consisting of: (15,3A)-RSL3, ML-162, ML-210, JKE-1674, JKE-1716, erastin, jacaric acid, buthionine sulfoximine (BSO), trigonelline, glutamate, sulfasalazine, auranofin, brusatol, sorafenib, sorafenib-d3, sorafenib tosylate, trigonelline, FIN56, FINO2, CIL56, dihydroisotanshinone I, GPX4-IN-3, analogs, and derivatives thereof, or a pharmaceutically acceptable salt of any of the foregoing.
• the iron-dependent cell death agent contacts the tissue at a localized site for about 6 hours. Further provided herein are methods, wherein the iron-dependent cell death agent contacts the tissue at a localized site for about 10 hours. Further provided herein are methods, wherein the iron-dependent cell death agent contacts the tissue at a localized site on the tumor for about 24 hours. Further provided herein are methods, wherein the iron-dependent cell death agent contacts the tissue at a localized site on the tumor for about 48 hours. Further provided herein are methods, wherein the iron-dependent cell death agent contacts the tissue at a localized site on the tumor for about 72 hours. Further provided herein are methods, wherein the tissue is a tumor or a pre-cancerous lesion.
• the tumor is resistant to one or more anti-apoptosis agents.
• the tumor is a carcinoma, a melanoma, or a sarcoma.
• the melanoma is a dedifferentiated melanoma or a amelanotic melanoma.
• the method further comprises a step of obtaining a biopsy of the tissue for histological analysis.
• the tissue comprises a histological abnormality, wherein the histological abnormality is hyperplasia or fibrosis.
• the one or more markers indicative of a mesenchymal state is/are selected from the group consisting of: ZEB1, ACSL4, FADS2, PPARy, Fspl, SLC7A11, SLC3A2, and LPCAT3.
• the tissue comprises a plurality of cells that have a reduction in the expression of one or more endothelial cell markers.
• the endothelial cell marker is selected from the group consisting of: vimentin, E-cadherin, and beta (P)-actin.
• the iron-dependent cell death agent reduces tissue size or tissue volume by at least 5%.
• the iron-dependent cell death agent is administered with one additional agent.
• the one additional agent is a cell death-inducing agent or a dietary supplement.
• the methods comprise: (a) contacting a mammalian tissue with a priming agent; (b) contacting the mammalian tissue in vivo with an effective amount of a ferroptosis- inducing agent for a duration of time of at least 4 hours, wherein a plurality of cells within the mammalian tissue are responsive to the priming agent as determined by detecting in the mammalian tissue: (i) a plurality of cells comprising a concentration of selenium greater than a selenium concentration in the mammalian tissue prior to contacting with the priming agent; (ii) a plurality of cells comprising a concentration of iron greater than an iron concentration in the mammalian tissue prior to contacting with the priming agent; (iii) a plurality of cells comprising a PUFA concentration greater than a PUFA concentration in the mammalian tissue prior to contacting with the
• step (a) is performed, in vivo, in vitro, or ex vivo.
• the methods further comprise a step of obtaining a biopsy of the mammalian tissue for histological analysis.
• the methods further comprise a step of detecting a plurality of cells within the mammalian tissue as responsive to the priming agent.
• the detecting is via a histological assay or an immunohistochemical assay.
• the priming agent is any one of the agents listed in Table 2.
• priming agent is priming agent is selected from the group consisting of: liproxstatin-1, ferrostatin-1, deferoxamine (DFO), iron, vitamin E, a polyunsaturated fatty acid, or selenium.
• methods further comprise administering a cell death-inducing agent.
• the cell-death inducing agent is a chemotherapeutic agent.
• ferroptosis-inducing agent is any one of the agents listed in Table 1.
• ferroptosis-inducing agent is selected from Table 1, for instance, from the group consisting of (1S,3R)-RSL3, ML-162, ML-210, JKE-1674, JKE-1716, erastin, jacaric acid, buthionine sulfoximine (BSO), trigonelline, glutamate, sulfasalazine, auranofin, brusatol, sorafenib, sorafenib-d3, sorafenib tosylate, trigonelline, FIN56, FINO2, CIL56, dihydroisotanshinone I, GPX4-IN-3, analogs, and derivatives thereof.
• Table 1 for instance, from the group consisting of (1S,3R)-RSL3, ML-162, ML-210, JKE-1674, JKE-1716, erastin, jacaric acid, buthionine sulfoximine (BSO), trigonel
• ferroptosis-inducing agent contacts the mammalian tissue for about 6 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the mammalian tissue for about 10 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the mammalian tissue for about 24 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the mammalian tissue for about 48 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the mammalian tissue for about 72 hours.
• the effective amount of the ferroptosis-inducing agent is a concentration of at least about 1 pM to 10 pM.
• cell death can be detected at a time point at or after contacting the mammalian tissue with the ferroptosis-inducing agent.
• methods, wherein following contact with the ferroptosis-inducing agent or the iron dependent cell death agent, immune cell recruitment can be detected at a time point at or after contacting the mammalian tissue with the ferroptosis- inducing agent or the iron dependent cell death agent.
• the tissue is human tissue.
• sustained administration or contacting step is via intratumoral injection, oral administration, transdermal injection, inhalation, nasal administration, topical administration, vaginal administration, ophthalmic administration, intracerebral administration, rectal administration.
• sustained administration or contacting step is via intravenous administration, intra-arterial administration, intramuscular administration, or subcutaneous administration.
• an implantable microdevice configured for localized administration to a tissue comprising: (a) a cylindrical support structure having at least one microwell on a surface of or formed within the support structure; (b) a microdose of a ferroptosis-inducing agent in the at least one microwell; and (c) a compound release mechanism for sustained administration for controlling a release of the ferroptosis-inducing agent from the microwell, wherein the microdose of the ferroptosis-inducing agent forms a gradient of a sub-therapeutic amount of the ferroptosis-inducing agent to an administration site within the tissue for a duration of time of at least 4 hours, wherein the microdevice is configured to permit implantation into the tissue using a catheter, cannula or biopsy needle, wherein the microdevice is further configured to release the ferroptosis-inducing agent from the at least one microwell to the administration site within the apoptosis-resistant tissue adjacent
• systems for screening for ferroptosis-induced cell death in vivo comprising: (a) an animal model comprising a target tissue of interest; (b) a microdevice configured to permit implantation into a tissue in the animal model using a catheter, cannula or biopsy needle comprising: (i) at least one microwell containing one or more active agents; (ii) at least one microwell containing one or more ferroptosis inhibitors; (ii) a micro-dose of the one or more active agents; and/or one or more ferroptosis inhibitors in the at least one microwell; and (iii) a compound release mechanism comprising a polymeric matrix for controlling the release of the one or more active agents from the microwell into the tissue; wherein the system measures an outcome of ferroptosis induction in the animal model after administration of the one or more active agents into the tissue relative to a baseline tissue without administration of the one or more active agents, wherein the system measures an outcome of ferroptosis
• systems for screening for ferroptosis-induced cell death in vivo comprising: (a) an animal model comprising a target tissue of interest; (b) a microdevice configured to permit implantation into a tissue in the animal model using a catheter, cannula or biopsy needle comprising: (i) at least one microwell containing one or more active agents; (ii) at least one microwell containing one or more ferroptosis inhibitors; (ii) a micro-dose of the one or more active agents; and/or one or more ferroptosis inhibitors in the at least one microwell; and (iii) a compound release mechanism comprising a polymeric matrix for controlling the release of the one or more active agents from the microwell into the tissue; wherein the system measures an outcome of ferroptosis induction in the animal model after administration of the one or more active agents into the tissue relative to a baseline tissue without administration of the one or more active agents, wherein the system measures an outcome of ferroptosis
• ferroptosis inhibitor is liproxstatin-1, ferrostatin-1, deferoxamine (DFO), iron, vitamin E, a polyunsaturated fatty acid, or selenium.
• ferroptosis-inducing agent is an inhibitor of glutathione peroxidase 4 (GPX4), glutathione synthetase, glutamate-cysteine ligase, phosphoseryl-TRNA Kinase (PSTK), Eukaryotic Elongation Factor Selenocysteine-TRNA Specific (EEFSEC), Selenophosphate Synthetase 2 (SEPHS2), Sep (O-Phosphoserine) TRNA:Sec (Selenocysteine) TRNA Synthase (SEPSECS), or SECIS Binding Protein 2 (SECISBP2).
• GPX4 glutathione peroxidase 4
• glutathione synthetase glutamate-cysteine ligase
• ferroptosis-inducing agent is selected from the group consisting of: (1S,3R)-RSL3, ML-162, ML- 210, JKE-1674, JKE-1716, erastin, jacaric acid, buthionine sulfoximine (BSO), trigonelline, glutamate, sulfasalazine, auranofin, brusatol, sorafenib, sorafenib-d3, sorafenib tosylate, trigonelline, FIN56, FINCh, CIL56, dihydroisotanshinone I, GPX4-IN-3, analogs, and derivatives thereof.
• BSO buthionine sulfoximine
• ferroptosis-inducing agent contacts the mammalian tissue for about 6 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the mammalian tissue for about 10 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the mammalian tissue for about 24 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the mammalian tissue for about 48 hours. Further provided herein are methods, wherein the ferroptosis-inducing agent contacts the mammalian tissue for about 72 hours.
• the effective amount of the ferroptosis-inducing agent is a concentration of at least about 1 pM to 10 pM.
• cell death can be detected at a time point at or after contacting the mammalian tissue with the ferroptosis-inducing agent.
• immune cell recruitment can be detected at a time point at or after contacting the mammalian tissue with the ferroptosis-inducing agent.
• the tissue is human tissue.
• administering or contacting step is via intratumoral injection, oral administration, transdermal injection, inhalation, nasal administration, topical administration, vaginal administration, ophthalmic administration, intracerebral administration, rectal administration. Further provided herein are methods, wherein the administering or contacting step is via intravenous administration, intra-arterial administration, intramuscular administration, or subcutaneous administration.
• the method further comprises measuring one or more parameters indicative of ferroptosis in the mammalian tissue, wherein the one or parameters are selected from: concentration of selenium; concentration of iron; PUFA concentration; expression one or more markers indicative of a mesenchymal state; peroxidizability index (PI); and/or cell proliferation.
• concentration of selenium concentration of iron
• PUFA concentration concentration of iron
• PI peroxidizability index
• a method of treating a cancer, a hyperplasia, or a fibrosis in a tissue of a subject by inducing ferroptosis in the tissue of the subject in vivo comprising: administering to the subject a ferroptosis-inducing agent in an amount sufficient to achieve a concentration of at least 1 pM of the ferroptosis-inducing agent in the tissue wherein the tissue of the subject is contacted with the ferroptosis-inducing agent for a period of at least 24 hours, thereby inducing ferroptosis in the tissue in vivo and treating the cancer hyperplasia, or a fibrosis in the tissue of the subject.
• ferroptosis- inducing agent is an inhibitor of glutamate-cysteine ligase.
• the achieved concentration of the ferroptosis-inducing agent in the tissue is from 0.1 pM to 10 pM and the ferroptosis-inducing agent is contacted with the tissue for a period of at least 48 hours.
• ferroptosis-inducing agent is an inhibitor of glutathione synthetase, glutamate-cysteine ligase, phosphoseryl-TRNA Kinase (PSTK), Eukaryotic Elongation Factor Selenocysteine-TRNA Specific (EEFSEC), Selenophosphate Synthetase 2 (SEPHS2), Sep (O-Phosphoserine) TRNA:Sec (Selenocysteine) TRNA Synthase (SEPSECS), or SECIS Binding Protein 2 (SECISBP2).
• the inhibitor is a small molecule, a peptide, or a nucleic acid.
• ferroptosis-inducing agent is selected from the group consisting of: (1S,3R)-RSL3, ML-162, ML-210, JKE-1674, JKE-1716, erastin, jacaric acid, buthionine sulfoximine (BSO), trigonelline, glutamate, sulfasalazine, auranofin, brusatol, trigonelline, FIN56, FINO2, CIL56, dihydroisotanshinone I, GPX4-IN-3, an analog of any of these, a derivative of any of these, and any combination of the foregoing.
• BSO buthionine sulfoximine
• the ferroptosis- inducing agent does not comprise an iron-oxide or a sorafenib.
• the tissue of the subject is contacted with the ferroptosis-inducing agent for a period of 24 hours to 48 hours.
• the tissue is cancerous and comprises a plurality of cancer cells.
• the tissue is cancerous, and comprises a carcinoma, a melanoma, or a sarcoma.
• tissue is cancerous and the tissue that is cancerous is selected from the group consisting of: breast, brain, pancreatic, prostate, skin, bladder, lung, liver, ovarian, renal, endometrial, colorectal, gastric, head and neck and thyroid.
• the ferroptosis-inducing agent reduces tissue size or tissue volume by at least 5%.
• the ferroptosis-inducing agent is administered with one additional agent.
• the additional agent is a cell death-inducing agent or a dietary supplement.
• a composition comprising a ferroptosis-inducing agent in an amount sufficient to achieve a concentration of at least 1 pM of the ferroptosis-inducing agent in the tissue and to achieve a distribution of 1 ng/mm 3 of the ferroptosis-inducing agent in the tissue for at least 4 hours, wherein the tissue of the subject is contacted with the ferroptosis-inducing agent for a period of at least 24 hours, thereby inducing ferroptosis in the tissue in vivo of the subject.
• the concentration of the ferroptosis-inducing agent achieved in tissue is from 1 pM to 10 pM.
• the method further comprises administering to the subject a priming agent prior to administering to the subject the ferroptosis-inducing agent.
• the administering comprises administering 10 pg of the ferroptosis-inducing agent per kg of subject body weight per day to 10,000 mg of the ferroptosis-inducing agent per kg of subject body weight per day.
• the tissue is cancerous, exhibits hyperplasia, or exhibits fibrosis.
• the concentration of the ferroptosis-inducing agent achieved in the tissue is from 1 pM to 10 pM; the administering comprises administering 10 pg of the ferroptosis-inducing agent per kg of subject body weight per day to 10,000 mg of the ferroptosis-inducing agent per kg of subject body weight per day; and the subject has a cancer, a fibrosis, or an autoimmune disease.
• the tissue of the subject is contacted with the ferroptosis-inducing agent for a period of 24 hours to 48 hours.
• the tissue is cancerous and comprises a plurality of cancer cells.
• the tissue is cancerous, and comprises a carcinoma, a melanoma, or a sarcoma.
• the tissue is cancerous and the tissue that is cancerous is selected from the group consisting of: breast, brain, pancreatic, prostate, skin, bladder, lung, liver, ovarian, renal, endometrial, colorectal, gastric, head and neck and thyroid.
• the ferroptosis- inducing agent reduces tissue size or tissue volume by at least 5%.
• the ferroptosis-inducing agent is administered with one additional agent.
• the additional agent is a cell death-inducing agent or a dietary supplement.
• a composition comprising a ferroptosis-inducing agent in an amount sufficient to achieve a concentration of at least 1 pM of the ferroptosis-inducing agent in the tissue and to achieve a distribution of 1 ng/mm3 of the ferroptosis-inducing agent in the tissue for at least 4 hours, wherein the tissue of the subject is contacted with the ferroptosis-inducing agent for a period of at least 24 hours, thereby inducing ferroptosis in the tissue in vivo of the subject.
• the concentration of the ferroptosis-inducing agent achieved in tissue is from 1 pM to 10 pM.
• the method further comprises administering to the subject a priming agent prior to administering to the subject the ferroptosis-inducing agent.
• the administering comprises administering 10 pg of the ferroptosis-inducing agent per kg of subject body weight per day to 10,000 mg of the ferroptosis-inducing agent per kg of subject body weight per day.
• the tissue is cancerous, exhibits hyperplasia, or exhibits fibrosis.
• the concentration of the ferroptosis-inducing agent achieved in the tissue is from 1 pM to 10 pM; the administering comprises administering 10 pg of the ferroptosis-inducing agent per kg of subject body weight per day to 10,000 mg of the ferroptosis-inducing agent per kg of subject body weight per day; and the subject has a cancer, a fibrosis, or an autoimmune disease.
• a method of treating a cancer in a tissue of a subject by inducing ferroptosis in the tissue of the subject in vivo comprising: administering to the subject a priming agent; and administering to the subject a ferroptosis-inducing agent in an amount sufficient to achieve a concentration of at least 1 pM of the ferroptosis-inducing agent in the tissue wherein the tissue of the subject is contacted with the ferroptosis-inducing agent for a period of at least 24 hours, thereby inducing ferroptosis in the tissue in vivo and treating the cancer in the tissue of the subject.
• ferroptosis- inducing agent is an inhibitor of glutamate-cysteine ligase.
• the achieved concentration of the ferroptosis-inducing agent in the tissue is from 1 pM to 10 pM and the ferroptosis-inducing agent is contacted with the tissue for a period of at least 48 hours.
• ferroptosis-inducing agent is an inhibitor of glutathione synthetase, glutamate-cysteine ligase, phosphoseryl-TRNA Kinase (PSTK), Eukaryotic Elongation Factor Selenocysteine-TRNA Specific (EEFSEC), Selenophosphate Synthetase 2 (SEPHS2), Sep (O-Phosphoserine) TRNA:Sec (Selenocysteine) TRNA Synthase (SEPSECS), or SECIS Binding Protein 2 (SECISBP2).
• the inhibitor is a small molecule, a peptide, or a nucleic acid.
• ferroptosis-inducing agent is selected from the group consisting of: (1S,3R)-RSL3, ML-162, ML-210, JKE-1674, JKE-1716, erastin, jacaric acid, buthionine sulfoximine (BSO), trigonelline, glutamate, sulfasalazine, auranofin, brusatol, trigonelline, FIN56, FINO2, CIL56, dihydroisotanshinone I, GPX4-IN-3, an analog of any of these, a derivative of any of these, and any combination of the foregoing.
• BSO buthionine sulfoximine
• the ferroptosis-inducing agent does not comprise an iron-oxide or a sorafenib.
• the tissue of the subject is contacted with the ferroptosis-inducing agent for a period of 24 hours to 48 hours.
• the tissue is cancerous and comprises a plurality of cancer cells.
• the tissue is cancerous, and comprises a carcinoma, a melanoma, or a sarcoma.
• tissue is cancerous and the tissue that is cancerous is selected from the group consisting of: breast, brain, pancreatic, prostate, skin, bladder, lung, liver, ovarian, renal, endometrial, colorectal, gastric, head and neck and thyroid.
• the ferroptosis-inducing agent reduces tissue size or tissue volume by at least 5%.
• the ferroptosis-inducing agent is administered with one additional agent.
• the additional agent is a cell death-inducing agent or a dietary supplement.
• a method of inducing ferroptosis in vivo in a tissue of a subject comprising: administering to the subject a priming agent; and administering to the subject a composition comprising a ferroptosis-inducing agent in an amount sufficient to achieve a concentration of at least 1 pM of the ferroptosis-inducing in the tissue and to achieve a distribution of 10 ng/mm 3 of the ferroptosis-inducing agent in the tissue for at least 4 hours, wherein the tissue of the subject is contacted with the ferroptosis-inducing agent for a period of at least 24 hours, thereby inducing ferroptosis in the tissue in vivo of the subject.
• the concentration of the ferroptosis-inducing agent achieved in tissue is from 1 pM to 10 pM.
• the administering comprises administering 10 pg of the ferroptosis-inducing agent per kg of subject body weight per day to 10,000 mg of the ferroptosis-inducing agent per kg of subject body weight per day.
• the tissue is cancerous, exhibits hyperplasia, or exhibits fibrosis.
• the concentration of the ferroptosis-inducing agent achieved is the tissue is from 1 pM to 10 pM; the administering comprises administering 10 pg of the ferroptosis-inducing agent per kg of subject body weight per day to 10,000 mg of the ferroptosis-inducing agent per kg of subject body weight per day; and the subject has a cancer, a fibrosis, or an autoimmune disease.
• the concentration of the ferroptosis-inducing agent achieved in the tissue is from 1 pM to 10 pM; the administering comprises administering 10 pg of the ferroptosis- inducing agent per kg of subject body weight per day to 10,000 mg of the ferroptosis-inducing agent per kg of subject body weight per day; and the subject has a cancer, a fibrosis, or an autoimmune disease
• compositions for the treatment of a disease or disorder wherein the compositions comprise any one of the agents in Table 1 or a combination of agents; and a system provided herein.
• pharmaceutical compositions for the treatment of a disease or disorder wherein the pharmaceutical compositions comprise any one of the agents in Table 1 or a combination of agents; and a pharmaceutically acceptable excipient.
• pharmaceutical compositions for the treatment of a disease or disorder wherein the pharmaceutical compositions comprise any one of the agents in Table 1, Table 2, or a combination of agents; and a pharmaceutically acceptable excipient.
• Example 1 Cell lines and culture conditions
• Human cancer cell lines are cultured in Ham’s F12 medium supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100 U/mL), and streptomycin (100 pg/mL).
• human cancer cells are cultured in RPMI medium supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100 pg/mL).
• Cells are grown in a humidified incubator at 37 °C with 5% carbon dioxide and split every 3-4 days using trypsin/EDTA solution.
• Lipidomics are performed using either gas chromatography-mass spectrometry (GC-MS) or direct infusion mass spectrometry.
• the membrane lipids are trans-esterified with 500 pL methanolic HC1, 250 pL n-hexane and 500 pL internal standard (0.8 mg Di-C17- phosphatidylcholine in 1 mL methanol with 0.2% Butylhydroxytoluol as antioxidant). After cooling-off, 500 pL n-hexane and 1 mL Aqua Dest. are added. The upper hexane phase is evaporated with nitrogen. The fatty acid methylesters (FAME) are taken up in 60 pL n-hexane.
• FAME fatty acid methylesters
• lipids are extracted using a two-step chloroform/methanol procedure. Samples are spiked with internal lipid standard mixture containing: cardiolipin 16: 1/15:0/15:0/15:0 (CL), ceramide 18: l;2/17:0 (Cer), diacylglycerol 17:0/17:0 (DAG), hexosylceramide 18: l;2/12:0 (HexCer), lyso-phosphatidate 17:0 (LPA), lyso- phosphatidylcholine 12:0 (LPC), lyso-phosphatidylethanolamine 17: 1 (LPE), lyso- phosphatidylglycerol 17: 1 (LPG), lyso-phosphatidylinositol 17: 1 (LPI), lyso-phosphatidylserine 17: 1 (LPS), phosphatidate 17:0/17:0 (PA), phosphatid
• the organic phase is transferred to an infusion plate and dried in a speed vacuum concentrator.
• the dried extract is re-suspended in 7.5 mM ammonium acetate in chloroform/methanol/propanol (1 :2:4, V:V:V) and the second step dry extract is re-suspended in a 33% ethanol solution of methylamine in chloroform/methanol (0.003:5: 1; V:V:V).
• Samples are analyzed by direct infusion on a QExactive mass spectrometer (ThermoFisher Scientific) equipped with a TriVersa NanoMate ion source (Advion Biosciences).
• MS-MS tandem mass spectrometry
• Example 3 Cell line profiling with a ferroptosis-inducing agent with and without a rescue agent
• Cell viability assays are performed by seeding 1,000 cells per well (30 pl volume) in opaque white 384-well plates (Corning). Cells are allowed to adhere for 24 hours, after which they are exposed to compounds for 72 hours. DMSO stock solutions of compounds are added to cells using a CyBio Well Vario liquid dispenser (Analytik Jena AG). Cellular ATP levels are measured using CellTiter-Glo (Promega) as a surrogate for viability.
• Rescue assays are performed using rescue agents selected from the agents in Table 2 and referred to in the assays as anti-ferroptosis rescue agent (N) (N, 1.5 pM), anti-ferroptosis rescue agent (M) (M, 1 pM), anti-ferroptosis rescue agent (P) (P, 50 pM), and other rescue agents/ferroptosis inhibitors added to cells at the time of addition to assay plates.
• N anti-ferroptosis rescue agent
• M anti-ferroptosis rescue agent
• P anti-ferroptosis rescue agent
• P anti-ferroptosis rescue agent
• other rescue agents/ferroptosis inhibitors added to cells at the time of addition to assay plates.
• lentiviral shRNA production 293-T cells are seeded in 6-well dishes in antibiotic free media (280,000 cells/well). The next day, cells were transfected using FuGENE with the appropriate shRNA encoding plasmid (450 ng), viral packaging plasmid (p-Delta8.9, 400 ng), and viral envelope plasmid (p-VSV-G, 45 ng). After 24 hours, the medium is removed and replaced with fresh medium. Three collections of viral supernatant per shRNA are made over 36 hours and pooled. The combined supernatant is centrifuged, aliquoted, and stored at -80 degrees C until virus infection.
• Lentiviral infections are performed by seeding cells for 12 hours and replacing the media with media supplemented with polybrene (8 pg/mL) and an aliquot of the viral supernatant. Plates are incubated for 48 hours and the media is replaced with media containing 1.5 pg/mL puromycin and incubated at 37 degrees C for 48 hours. Ocurrance of gene knock outs is assessed by immunoblotting and RT-qPCR.
• lentiviruses are generated by overnight polyethylenimine transfection of Leni-X 293T cells with target lentiviral plasmid and packaging plasmids pCMV-dR8.2 dvpr and pCMV-VSV-G in DMEM supplemented with 10% FBS. The next day, the medium is changed to fresh DMEM with 10% FBS. After 24 and 48 hours, the virus-containing medium is collected and filtered with a 0.45 pm polyethersulfone filter, combined, and stored at -80 degrees C until virus infection.
• Cells are transduced with pLenti-CRISPR-V2 encoding the appropriate sgRNAs for the target genes using 2 pg/mL of polybrene followed by puromycin selection (1 pg/mL) for 4 days in the presence of ferrostatin-1 (1 pM). Protein knockout is verified via immunoblotting.
• Example 4 Use of Cll-BODIPY to show lipid peroxidation as an indicator of ferroptosis
• Imaging assay human cancer cells are seeded at 5,000 cells per well in a CellCarrier Ultra 96-well plate (Perkin-Elmer) in 150 pl of RPMI medium with 10% FBS. Cells are incubated for 24 hours at 37 °C and then treated with the indicated compounds or DMSO (90 minutes, 37 °C). During the last 30 minutes of incubation, 60 nM DRAQ7 (Abeam), 1 pg ml -1 Hoechst 33342 (ThermoFisher) and 1 pM BODIPY 581/591 Cl l (ThermoFisher) dyes are added.
• Cells are imaged using an Opera Phenix High-Content Screening System (Perkin-Elmer) equipped with 405, 488, 560 and 647 nm lasers. Image analysis is conducted with Harmony High-Content Imaging and Analysis software (Perkin-Elmer).
• Human cancer cells are seeded at 15,000 cells per well in 96-well plates in RPMI medium with 10% FBS. After 48 hours, culture media is replaced with 200 pL media containing either DMSO or the indicated inhibitor (10 pM) and 1 pM anti-ferroptosis rescue agent (where indicated). Cultures are incubated at 37 °C for 2 hours. Thirty minutes before the end of the incubation period, 10 pM BODIPY 581/591 Cl l (Molecular Probes no. C10445) is added to cells. Cells are gathered in 200 pL PBS + 0.1% BSA and subjected to flow cytometry analysis (BD FACSCanto II).
• BD FACSCanto II flow cytometry analysis
• Example 5 Microdosing tumors with ferroptosis-inducing agents.
• cancer cell line-derived tumor cells were injected into the flanks of male C57BL6/J mice. Assays were initiated when the tumor diameter was approximately 6-7 mm.
• Microdose drug delivery was performed for the assay described herein.
• the compounds in Table 3 were packed into device reservoirs using a tapered metal needle. High loading concentrations are indicated, for example, in column 3 of Table 3. Low loading concentrations are indicated, for example in column 3 of Table 3.
• Reservoirs were loaded for initial release of anti-ferroptosis rescue agent (M) (where included) followed by a 4-6 hours delayed release of ferroptosis inducers.
• Devices were prepared for dose administration into mouse tumors. Devices delivered the ferroptosis inducing agent for 24-72 hours in the tissue. The tumor was then excised, and the tissue was snap frozen with liquid nitrogen. Tissue was sectioned using a standard cryotome, and tissue slices of 20 pm in thickness were collected from each reservoir for analysis by immunoassays, transcriptomics, and metabolomic assays.
• Example 6 Ferroptosis induction by sustained, targeted administration of ferroptosis- inducing agent (A)
• a drug delivery system was applied to a: solid tumor animal model. Animals were administered (1) ferroptosis-inducing agent (A) or (2) ferroptosis-inducing agent (A) + anti- ferroptosis rescue agent (M) as a ferroptosis-rescue agent. Drugs were loaded into an implantable drug delivery system to achieve concentrations of 1-10 pM for both ferroptosis-inducing agent (A) and ferroptosis-inducing compound (A) + anti-ferroptosis rescue agent (M) at the tumor site.
• A ferroptosis-inducing agent
• M anti-ferroptosis rescue agent
• ferroptosis-inducing compound (A)-treated tumor section shows the recruitment of white blood cells to the tumor indicating immune cell recruitment and cell death at the tumor site.
• the cells used to generate the tumors that were treated locally with ferroptosis-inducing compound (A) also exhibited significant reductions in fractional viability measured in vitro, as compared with ferroptosis-inducing compound (A) + anti-ferroptosis rescue agent (N) treated sections of the tumor (FIG. 2B). Therefore, ferroptosis can be induced by both local and systemic administration of ferroptosis-inducing agent (A).
• Example 7 Ferroptosis induction by sustained, targeted administration of ferroptosis- inducing agent (B)
• a drug delivery system was applied to a: solid tumor animal model.
• Animals were administered (1) ferroptosis-inducing agent (B) or (2) ferroptosis-inducing agent (B) + anti- ferroptosis rescue agent (M), as a ferroptosis rescue agent.
• Drugs were loaded into an implantable drug delivery system to achieve concentrations of 1-10 pM for both ferroptosis- inducing agent (B) and ferroptosis-inducing agent (B) + anti-ferroptosis rescue agent (M) at the tumor site in vivo.
• After 24 hours, tumors were removed and stained for cleaved caspase-3.
• the ferroptosis-inducing agent (B) treated tumor section shows the recruitment of white blood cells to the tumor indicating immune cell recruitment and cell death at the tumor site (FIG. 3).
• Example 8 Ferroptosis induction by administration of ferroptosis-inducing agent (C)
• ferroptosis-inducing agent (C) and anti- ferroptosis rescue agent (N) showed a reduction in the fractional viability of cancer cells that was not observed with ferroptosis-inducing agent (A) + anti-ferroptosis rescue agent (N), indicating that ferroptosis-inducing agent (C) is a robust inducer of ferroptosis.
• ferroptosis-inducing agent (C) To achieve therapeutic doses of ferroptosis-inducing agent (C) in vivo, a drug delivery system was applied to a: solid tumor animal model. Animals were administered (1) ferroptosis- inducing agent (C) or (2) ferroptosis-inducing agent (C) + anti-ferroptosis rescue agent (M) as a ferroptosis rescue agent. Drugs were loaded into an implantable drug delivery system to achieve concentrations of 1-10 pM for both ferroptosis-inducing agent (C) and ferroptosis-inducing agent (C) and anti-ferroptosis rescue agent (M) co-administration at the tumor site.
• C ferroptosis-inducing agent
• M anti-ferroptosis rescue agent
• FIG. 5A shows representative H&E images at 18 hours post treatment with (1) ferroptosis-inducing agent (C) or (2) ferroptosis-inducing agent (C) + anti-ferroptosis rescue agent (M) as indicated.
• White blood cell recruitment and cell death were prominent in ferroptosis-inducing agent (C) treated tumor sections as compared with ferroptosis- inducing agent (C) + anti-ferroptosis rescue agent (M) treated tumor sections.
• Example 9 System for in vivo ferroptosis-inducing agent delivery
• Ferroptosis-inducing agents and/or priming agents are administered systemically by injection to a mammal to establish local pharmacokinetics for the drugs.
• Representative drugs include: ferroptosis-inducing agent (A), ferroptosis-inducing agent (C), ferroptosis- inducing agent (B), and anti-ferroptosis rescue agent (M).
• Representative animal models that can be used include for instance, those harboring tumors in a flammable membrane state.
• a drug delivery system with microwells is loaded with approximately 1.5 micrograms of a ferroptosis-inducing agent (crystalline powder) per microwell.
• the system is loaded with the same drugs based on the results of the systemic testing.
• Each drug is loaded separately and in more than one concentration, as well as in combination.
• devices are removed and histology of the tissue was examined to determine the effect of the ferroptosis-inducing agents on the tumor cells adjacent to each well. The effects of compounds eluted from microwells are assessed by different techniques. Tissue excised with the device is assayed by standard histopathological techniques, including immunohistochemistry and immunofluorescence.
• Ingrowth of tissue ranging from 20 to about 300 microns, are visualized by staining tissue/device section by standard immuno-histochemistry (IHC) techniques, including hematoxylin & eosin (H&E) staining, or any nuclear cell stain such as DAPI.
• IHC immuno-histochemistry
• H&E hematoxylin & eosin
• DAPI nuclear cell stain
• Mass spectrometry can be used to measure local biomarkers indicative of an effect of a ferroptosis-inducing agent (e.g., mesenchymal cell state markers or PUFA concentration). Analysis for apoptosis, necrosis, mitotic cell death, and proliferation is conducted. The local microdose response is determined and used to define an appropriate therapeutic regime for the cancer.
• ferroptosis-inducing agent e.g., mesenchymal cell state markers or PUFA concentration
• Agents are released upward and diffused into a larger region, or released downward into a relatively smaller region of a target tissue.
• the precise control over the transport time as a function of distance from microwells provide a local concentration of a first agent as a function of distance from the microwell, at multiple time points following in vivo implantation.
• Concentration gradient regions are defined as the distance from the microwell increases, the concentration of the agent being administered decreases. Cleaved caspase 3 positive cells as percent area of 3, 3 '-diaminobenzidine (DAB) staining as a function of distance from the microwell is one example of a functional readout from the implanted drug delivery system.
• DAB 3 '-diaminobenzidine staining as a function of distance from the microwell is one example of a functional readout from the implanted drug delivery system.
• the agent concentration gradient is formed approximately 100-250 pm from the microwell with tissue concentration as greatest in the regions closest to the microwell.
• the system is used to deliver a microdose of a ferroptosis-inducing agent to a tissue in vivo.
• the system is also used to deliver a priming agent (e.g., anti-ferroptosis rescue agent (M)), followed by a ferroptosis-inducing agent (e.g., ferroptosis-inducing agent (C)) to a tissue in vivo to induce targeted cell death in the tissue.
• a priming agent e.g., anti-ferroptosis rescue agent (M)
• a ferroptosis-inducing agent e.g., ferroptosis-inducing agent (C)
• the system is also used to deliver a ferroptosis- inducing agent (e.g., ferroptosis-inducing agent (C)) to a tissue in vivo to induce targeted cell death in the tissue followed by delivering a priming agent (e.g., anti-ferroptosis rescue agent (M)).
• a ferroptosis- inducing agent e.g., ferroptosis-inducing agent (C)
• C ferroptosis-inducing agent
• M anti-ferroptosis rescue agent
• the system is also implanted directly into tumor of about 6 millimeters (mm) to about 7 mm in diameter to achieve a minimum amount of about 10 ng/mm 2 of drug at the site of the microwell for at least 4 hours.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=87074112

Family Applications (1)

Country Status (2)

Families Citing this family (1)

Family Cites Families (6)

• 2022
  • 2022-12-22 EP EP22919247.1A patent/EP4460299A4/de active Pending
  • 2022-12-22 WO PCT/US2022/082270 patent/WO2023133053A2/en not_active Ceased

Also Published As

Similar Documents

Legal Events